[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4033
1. Xiao Y, Gui X, Zhang D: [Alveolar carcinoma of lung with positive seral ANCA-report of a case and review of the literature.]. Zhongguo Fei Ai Za Zhi; 2008 Apr 20;11(2):294-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar carcinoma of lung with positive seral ANCA-report of a case and review of the literature.].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731923.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Roca Vanaclocha Y, Narváez JA, Pozuelo C, Monés L: [Alveolar microlithiasis: an uncommon cause of the crazy paving pattern]. Radiologia; 2008 Jan-Feb;50(1):75-8
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar microlithiasis: an uncommon cause of the crazy paving pattern].
  • [Transliterated title] Microlitiasis alveolar: presentación infrecuente del "patrón en empedrado"
  • Alveolar microlithiasis is an uncommon disease of unknown etiology characterized by the presence of multiple, predominantly subpleural, intra-alveolar microcalcifications.
  • This pattern is not specific for alveolar microlithiasis; it has also been reported in other entities, including alveolar proteinosis, lipoid pneumonia, and bronchial alveolar carcinoma.
  • [MeSH-major] Lithiasis / radiography. Lung Diseases / radiography. Pulmonary Alveoli / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275793.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Andela VB, Altuwaijri S, Wood J, Rosier RN: Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett; 2005 Mar 14;579(7):1765-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
  • We demonstrate expression and coordinate induction of PPARgamma and lipogenic enzymes (HMG-CoA synthase, HMG-CoA reductase and fatty acid synthase) in a murine lung alveolar carcinoma cell line (Line 1) treated with the PPARgamma agonist troglitazone (TRO) [0-100 microM].
  • These findings, suggest that inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / prevention & control. Adenosine Triphosphate / metabolism. Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Respiration / drug effects. Coenzyme A Ligases / genetics. Coenzyme A Ligases / metabolism. Fatty Acid Synthases / genetics. Fatty Acid Synthases / metabolism. Gene Expression / drug effects. Glucose / metabolism. Hydroxymethylglutaryl CoA Reductases / genetics. Hydroxymethylglutaryl CoA Reductases / metabolism. Hydroxymethylglutaryl-CoA Synthase. Lung Neoplasms / metabolism. Lung Neoplasms / prevention & control. Mice. Oxidation-Reduction / drug effects. Oxygen Consumption / drug effects

  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757673.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Fatty Acids; 0 / PPAR gamma; 0 / Thiazolidinediones; 8L70Q75FXE / Adenosine Triphosphate; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; EC 2.3.1.85 / Fatty Acid Synthases; EC 2.3.3.10 / Hydroxymethylglutaryl-CoA Synthase; EC 6.2.1.- / Coenzyme A Ligases; I66ZZ0ZN0E / troglitazone; IY9XDZ35W2 / Glucose; N9A0A0R9S8 / Trimetazidine
  •  go-up   go-down


Advertisement
4. Cadranel J, Lavolé A, Gounant V, Wislez M: [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S158-16S163
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
  • [Transliterated title] Formes cliniques des cancers thoraciques. Carcinome bronchiolo-alvéolaire (CBA) et adénocarcinome pulmonaire avec composante bronchiolo-alvéolaire (ADC-CBA): un continuum anatomo-clinique.
  • Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) arising in the cells of the terminal respiratory unit.
  • Although stage IIIB and IV tumours were excluded from the strict WHO definition of BAC the first international workshop on this tumour in 2004 emphasised the clinico-pathological continuum that exists between BAC as defined by WHO and ADC with BAC features (ADC-BAC).
  • BAC and ADC-BAC are distinguished from other non-small cell carcinomas by an increased incidence in women, non-smokers and Asians.
  • Surgery offers the best treatment for localised disease.
  • The high frequency of epidermal growth factor receptor (EGFR) expression and amplification and/or mutation of its gene, as well as the finding in some cases of a major response to EGFR tyrosine-kinase inhibitors, have lead to several therapeutic trials of these drugs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268353.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


5. Gottlieb J: [Chronic respiratory insufficiency: the role of lung transplantation]. Pneumologie; 2010 Sep;64(9):604-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic respiratory insufficiency: the role of lung transplantation].
  • Lung transplantation has been established as an appropriate ultimate treatment strategy in end-stage lung disease, when all conventional therapeutic options have been exhausted.
  • Acute and potentially reversible lung diseases (ARDS, pneumonia) and malignancy (broncho-alveolar carcinoma) are not established indications.
  • Retrospective analyses on the natural course of the disease and new medical treatment options have led to fewer transplantations in recipients with emphysema and idiopathic pulmonary hypertension.
  • In end-stage cystic fibrosis and patients with idiopathic pulmonary fibrosis, alternative treatment options are currently not available and lung transplantation is indicated.
  • [MeSH-major] Lung Transplantation / methods. Respiratory Insufficiency / complications. Respiratory Insufficiency / surgery
  • [MeSH-minor] Emphysema / surgery. Humans. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Patient Selection. Practice Guidelines as Topic. Quality of Life. Respiratory Distress Syndrome, Adult / surgery. Retrospective Studies. Survivors. Tissue Donors / statistics & numerical data. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20827647.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C, Brambilla E: Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res; 2010 Jun 1;16(11):2979-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere maintenance and DNA damage responses during lung carcinogenesis.
  • As their inactivation in cancer increases genetic instability, our objective was to identify the chronology of telomere machinery critical events for malignant progression.
  • EXPERIMENTAL DESIGN: We have evaluated telomere length by fluorescence in situ hybridization and analyzed DDR proteins p-CHK2, p-ATM, and p-H2AX, and telomeric maintenance proteins TRF1 and TRF2 expression by immunohistochemistry in normal bronchial/bronchiolar epithelium, and in 109 bronchial preneoplastic lesions, in comparison with 32 squamous invasive carcinoma (SCC), and in 27 atypical alveolar hyperplasia (AAH) in comparison with 6 adenocarcinoma in situ (AIS; formerly bronchiolo-alveolar carcinoma) and 24 invasive adenocarcinoma (ADC).
  • RESULTS: Telomere length critically shortened at bronchial metaplasia stage to increase gradually from dysplasia to invasive SCC; in bronchiolo-alveolar lesions, telomere length decreased from normal to AIS and increased from stage I to II to stage III to IV ADC.
  • CONCLUSION: Telomere attrition occurs at the earliest stage of lung carcinogenesis as an initiating event, preceding TRF1 and TRF2 overexpression for telomere stabilization.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. DNA Damage. Lung Neoplasms / genetics. Precancerous Conditions / genetics. Telomere / ultrastructure
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Carcinoma, Squamous Cell / genetics. Cell Cycle Proteins / metabolism. Checkpoint Kinase 2. DNA-Binding Proteins / metabolism. Disease Progression. Histones / metabolism. Hyperplasia / pathology. Immunohistochemistry. Lung / metabolism. Lung / pathology. Protein-Serine-Threonine Kinases / metabolism. Telomeric Repeat Binding Protein 1 / metabolism. Telomeric Repeat Binding Protein 2 / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20404006.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / H2AFX protein, human; 0 / Histones; 0 / TERF2 protein, human; 0 / Telomeric Repeat Binding Protein 1; 0 / Telomeric Repeat Binding Protein 2; 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


7. Andela VB, Schwarz EM, O'Keefe RJ, Puzas EJ, Rosenblatt JD, Rosier RN: A genome-wide expression profile and system-level integration of nuclear factor kappa B regulated genes reveals fundamental metabolic adaptations during cell growth and survival. FEBS Lett; 2005 Dec 19;579(30):6814-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genome-wide expression profile and system-level integration of nuclear factor kappa B regulated genes reveals fundamental metabolic adaptations during cell growth and survival.
  • A murine lung alveolar carcinoma cell line (WT-Line 1) and its equally tumorigenic but non-malignant derivative transduced with a dominant negative inhibitor of NF-kappaB (mI-kappaB-Line 1), were profiled on the Affymetrix 19000 gene array platform.
  • These findings are indicative of compensatory changes that could undermine anti-cancer therapies targeting NF-kappaB.
  • [MeSH-major] Adaptation, Physiological / genetics. Cell Division / genetics. Cell Survival / genetics. Gene Expression Profiling. NF-kappa B / genetics. NF-kappa B / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Genome. Mice. Oligonucleotide Array Sequence Analysis. Oxidation-Reduction. Proteins / genetics. Proteins / metabolism. Reactive Oxygen Species / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330031.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proteins; 0 / Reactive Oxygen Species
  •  go-up   go-down


8. Zell JA, Ou SH, Ziogas A, Anton-Culver H: Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol; 2006 Aug;17(8):1255-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis.
  • BACKGROUND: It has been suggested that the current staging system does not accurately reflect survival outcomes for advanced bronchiolo-alveolar carcinoma (BAC) patients.
  • Overall survival (OS) and lung cancer-specific survival (LCSS) univariate analyses were conducted using the Kaplan-Meier method.
  • RESULTS: 2345 incident cases of BAC were analyzed, including 707 patients with stage IIIB or IV BAC.
  • Patients with stage IIIB BAC due to multiple lesions in the same lobe (n=93) had significantly improved median OS (46m) and LCSS (>58m) compared to other stage IIIB BAC patients (n=111; OS=9m, P<0.0001; LCSS=10m, P<0.0001).
  • Among stage IV BAC patients, those with intrapulmonary metastasis (n=278) had significantly improved median OS (13m) and LCSS (15m) compared to those with distant metastasis (n=225; OS=7m, P<0.0001; LCSS=7m, P=0.0001).
  • CONCLUSIONS: Among stage IIIB and IV BAC patients, those presenting with ipsilateral intrapulmonary metastasis have improved survival outcomes.
  • Our results add further support for modification to the current staging system for BAC.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766595.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Subramanian J, Pillot G, Narra V, Govindan R: Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report. Lung Cancer; 2006 Feb;51(2):257-9
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report.
  • A 65-year-old male with 40-pack year smoking history presented with exertional dyspnea and was subsequently diagnosed with bronchiolo-alveolar carcinoma (BAC).
  • He did not respond to first line therapy with geftinib, but he achieved disease stabilization with gemcitabine and carboplatin for 4 months before developing symptomatic worsening requiring oxygen supplementation.
  • Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lung Neoplasms / drug therapy. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2007 Aug;57(2):249-50 [17599646.001]
  • (PMID = 16387387.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


10. Pasqualini ME, Berra MA, Calderón RO, Cremonezzi DC, Giraudo C, Eynard AR: Dietary lipids modulate eicosanoid release and apoptosis of cells of a murine lung alveolar carcinoma. Prostaglandins Leukot Essent Fatty Acids; 2005 Apr;72(4):235-40
MedlinePlus Health Information. consumer health - Dietary Fats.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary lipids modulate eicosanoid release and apoptosis of cells of a murine lung alveolar carcinoma.
  • Dietary arachidonic acid (AA) and eicosanoids influence neoplastic cell (NC) growth, differentiation and apoptosis.
  • Plasma membrane fatty acid and cyclooxygenase (COX) and lipoxygenase (LOX) products were investigated in lung alveolar carcinoma cells from mice fed on different diets.
  • High levels of AA and decreased COX eicosanoids has been involved in anti-tumoral mechanisms by increasing tumor cell apoptosis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / secretion. Apoptosis / drug effects. Dietary Fats / pharmacology. Eicosanoids / secretion
  • [MeSH-minor] Animals. Cell Membrane / metabolism. Fatty Acids / metabolism. Female. Lipoxygenase / metabolism. Mice. Mice, Inbred BALB C. Prostaglandin-Endoperoxide Synthases / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763434.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Eicosanoids; 0 / Fatty Acids; EC 1.13.11.12 / Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


16. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N: Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project. J Clin Oncol; 2009 May 20;27(15_suppl):1540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project.
  • : 1540 Background: We have investigated the individualized benefit of CT screening as Anti-Lung Cancer Association projects (presented at ASCO 2006-2008).
  • However, there has not been enough information about the relationship of lung cancer stage to tumor size in repeated CT screening.
  • Therefore, we evaluated the stage-size relationship of these asymptomatic lung cancer cases diagnosed by long-term repeated screening with low-dose helical CT.
  • Histology for the categories 15 mm or less was localized bronchioloalveolar carcinoma in 13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive adenocarcinoma in five cases, other non-small cell carcinoma in 10 cases, and small cell carcinoma in one case.
  • CONCLUSIONS: These results provide direct evidence of a stage-size relationship in long-term repeated CT screening for lung cancer.
  • Furthermore, early detection of lung cancer of 15 mm or less in diameter leads to the detection of early-stage (N0M0) lung cancer in repeated CT screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Osoegawa A, Takeda Y, Kometani T, Ondo K, Fukuyama S, Hirai F, Nosaki K, Seto T, Oda S, Ichinose Y: LKB1 mutations in mucinous bronchioloalveolar carcinoma occurring in Peutz-Jeghers syndrome patients. J Clin Oncol; 2009 May 20;27(15_suppl):11047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LKB1 mutations in mucinous bronchioloalveolar carcinoma occurring in Peutz-Jeghers syndrome patients.
  • : 11047 Background: Mutations in the gene encoding Liver Kinase B1, LKB1, are common in patients with Peutz-Jeghers syndrome (PJS), which is characterized by mucocutaneous pigmentation, intestinal polyps and a high incidence of cancers at variable sites (colorectal, gynecological, breast, pancreas, and lung).
  • Although tumors occurring in PJS patients are known to contain mucin-rich conmponents, mucinous bronchioloalveolar carcinomas (mBACs) arising from the PJS background have only rarely been reported.
  • CONCLUSIONS: The relatively high frequency of LKB1 mutation in mBAC patients may suggest its implication in lung carcinogenesis, at least in mBAC, and its potential as a therapeutic target.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Duhoux F, Libouton J, Bahloula K, Ameye G, Poirel HA: Identification by FISH of 4 novel partner loci of PRDM16 in myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):11037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11037 Background: PRDM16 is a gene located on 1p36.32 that encodes for a zinc finger transcription factor and contains an N-terminal PR domain.
  • These translocations result in the overexpression of a truncated version of the PRDM16 protein that lacks the PR domain.
  • METHODS: We studied 35 myeloid malignancies, 12 lymphoid malignancies and 3 undifferentiated acute leukemias with 1p36 abnormalities by fluorescent in situ hybridization (FISH) with a bacterial artificial chromosomes (BAC) contig containing 50 BAC probes on 1p36.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA: Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):8065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma.
  • : 8065 Background: This single-arm phase II study explored the role of clinical characteristics (female gender, adenocarcinoma histology, no tobacco within 1 year) in selecting pts for 1st-line therapy w/ erlotinib.
  • METHODS: Eligible pts were chemotherapy-naïve women, stage IIIB/ IV, PS 0-2, adenocarcinoma, and w/ available tissue for analysis of EGFR mutation status.
  • Pts received erlotinib 150 mg PO daily until disease progression or unacceptable toxicity.
  • Median age 68 (range 34-88); 59 PS 0, 24 PS 1, 1 PS 2; race: 79 white, 3 Asian, 2 black; 16 pts had BAC or predominant BAC features; smoking status: 35 never, 49 former.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962638.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gaile DP, Shepherd L, Liu S, Darcy K, Brady M, Morrison C: iGenomicViewer, a Gynecologic Oncology Group software library for the creation of highly customizable, portable, interactive, and linked visualizations of high throughput genomic data. J Clin Oncol; 2009 May 20;27(15_suppl):e16544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A set of R functions were created to extend the functionality of the sendplot R library.
  • The functions were applied to BAC aCGH data generated for several GOG studies.
  • 2) a set of interactive annotation tracks which display location of cancer, disease and DNA repair genes; and 3) a plot which displays -log10 p-values and/or aberration frequencies for the BAC assays depicted in the heatmap.
  • For the smallest regions of interest, the panel of plots contains a tiled heatmap which depicts the overlap and gaps in BAC coverage and their alignment with the gene locations represented in the adjacent annotation track.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960821.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gadaleta C, Catino A, Rubini G, Ranieri G, Fazio V, Gadaleta-Caldarola G, Vinciarelli G, Armenise F, Gaudiano A, Mattioli V: Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: Initial experience in twelve cases. J Clin Oncol; 2009 May 20;27(15_suppl):7593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: Initial experience in twelve cases.
  • : 7593 Background: The study aimed to evaluate the feasibility and safety of precision pulmonary arterial chemoembolization (PPTACE) followed by percutaneous RFA in patients with unresectable lung neoplasms Methods: From November 2007 to October 2008, twelve patients (5 male, 7 female, median age 57) and 20 nodules were treated in 14 sessions.
  • Patients had lung metastases from the following tumors: uterine cancer (2), colorectal carcinoma (7), breast carcinoma (1) and two patients had primary unresectable NSCLC.
  • Two patients underwent two sessions of treatment due to bilateral disease.
  • Percutaneous CT-guided RFA of lung nodules was performed 2-7 days after PPTACE.
  • Pretreatment work-up included: contrast-enhanced CT-scan, (18-F)Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) and Ventilation Lung Single Photon Emission Tomography (VL-SPET).
  • VL-SPET showed a wide area without ventilation in lung parenchyma submitted to PPTACE and extending over it; the changes on alveolar ventilation detected by VL- SPET after PPTACE could explain the better heat conduction during RFA.
  • CONCLUSIONS: Lung RFA after pulmonary TACE is feasible and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Nakayama H, Kato Y, Tsuboi M, Okumura S, Daisaki H, Uehara H, Adachi S, Yoshimura M, Okada M: Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):7573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study.
  • : 7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy.
  • We examined the malignancy grade of small lung ADs using FDG-PET/CT (PET), in addition to high-resolution CT (HRCT) and pathologic evaluation in a multicenter setting.
  • METHODS: A total of 204 patients with cT1N0M0 AD underwent PET and HRCT, followed by complete resection with lymph node dissection.
  • The associations between components of bronchioloalveolar carcinoma (BAC) on pathologic examination and maximum standardized uptake value (maxSUV) on PET, ground-glass opacity (GGO) ratio and tumor disappearance rate (TDR) on HRCT were examined, and these findings were analyzed in relation to pathologic features and surgical outcomes.
  • RESULTS: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade.
  • MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival.
  • Although BAC ratio was significantly associated with maxSUV, GGO ratio and TDR (all p<0.0001), the degree of association with maxSUV (R2=0.2533) was weaker than that with GGO (R2=0.5843) ratio or TDR (R2=0.5123).
  • CONCLUSIONS: A higher maxSUV reflects an aggressive malignant behavior of cT1N0M0 ADs, independently of BAC component.
  • Assessment by PET in addition to HRCT is useful for selection of the appropriate treatment strategy for small lung AD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Soto Parra HJ, Ippolito M, Tiseo M, Cosentino S, Ardizzoni A, Latteri F, Pumo V, Cordio S, Bordonaro R, Spadaro P: Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: Results of a pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):7568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: Results of a pilot study.
  • Glucose metabolic activity seems to closely reflect response to epidermal growth factor receptor (EGFR) TKI in vivo and in vitro (Su H et al, Clin Cancer Res 2006;12:5659-67).
  • RESULTS: From May 2007, 27 pts were enrolled and 23 were evaluable (4 not-evaluable: 2 BAC PET negative, 2 violations).
  • FDG-PET revealed a metabolic partial response (PR) in 8 pts; subsequent CT scan assessment evidenced 4 PR and 4 long lasting stable disease (SD), respectively.
  • Seven pts had metabolic progressive disease (PD) at PET scan and 8 had SD, all of them presented PD at CT scan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963364.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban Gonzalez E, Molinier O, Klingelschmitt G, Giaccone G, SATURN Investigators: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):8001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with no evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 mg/day or P until progression or unacceptable toxicity.
  • Baseline characteristics for E and P arms (%): male/female: 73/27 and 75/25; adenocarcinoma + BAC/squamous-cell/other: 47/38/15 and 44/43/13; stage IIIB/IV: 26/74 and 24/76; Caucasian/Asian/other: 84/14/2 and 83/15/2; ECOG PS 0/1: 31/69 and 32/68; current/former/never smoker: 55/28/18 and 56/27/17.
  • Disease control rate (complete response + partial response + stable disease >12 wks) was 40.8% with E versus 27.4% with P (p<.0001).
  • Erlotinib in the 1st-line maintenance setting is well tolerated, and significantly improves disease control and delays progression versus placebo across patient subgroups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Vinolas N, Magem M, Garrido P, Artal A, De Castro J, Campelo RG, Isla D, Felip E, Amador M, Rosell R: Lung cancer in women: The Spanish female-specific database WORLD 07. J Clin Oncol; 2009 May 20;27(15_suppl):8084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in women: The Spanish female-specific database WORLD 07.
  • : 8084 Background: Lung cancer is the leading cause of cancer mortality among women in many countries.
  • METHODS: WORLD07 is a prospective, multicenter, epidemiologic female-specific lung cancer database developed by the Spanish Lung Cancer Group.
  • Data on demographics, previous cancer history, reproductive and hormonal status, diet, alcohol, tobacco, and occupational information are being collected just as histology, stage, treatment and survival.
  • RESULTS: From October 2007 to Nov 2008, 342 female newly diagnosed of lung cancer were collected in an e-database in 20 Spanish centers.
  • Familial history of cancer: 45.5% (lung cancer 29.7%).
  • Previous history of cancer 13.8% (breast 33.3%).
  • Current lung cancer histology (%): adenocarcinoma/BAC/squamous/large cell/NOS: 70.4/5.7/10.4/7.9/5.7.
  • CONCLUSIONS: According this series, 42% of Spanish lung cancer women are never smokers and 70.4% have adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962661.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Zhong W, Yang X, Guo A, Su J, Zhang X, Chen H, Qiao G, Liao R, Yang J, Wu Y: Genetic evolution of EGFR and the clonal origin of adenocarcinomas exhibiting various degrees of bronchioloalveolar carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic evolution of EGFR and the clonal origin of adenocarcinomas exhibiting various degrees of bronchioloalveolar carcinoma.
  • : e22050 Background: EGFR mutations may accumulate during multistage progression of bronchioloalveolar carcinoma (BAC), leading to heterogeneity within the tumor.
  • Moreover, intrapulmonary emersions are the predominant sites of BAC progression in the absence of other distant metastases.
  • In cases of emerging bilateral lung lesions during the follow-up to complete resection, the issue of how to differentiate between lesions originating from multifocal BACs or distant metastases/local recurrence is an important and unresolved issue.
  • This study was performed to determine whether sequential adenocarcinoma with BAC features emerges in the lung field arises from a single clone or multiple clones in the same individual.
  • METHODS: Samples of adenocarcinomas exhibiting various degrees of BAC were obtained by thoracotomy.
  • Sequential specimens were obtained on detection of novel lesions in the lung field.
  • Our pathological findings, sequential imaging, and EGFR sequence data were compared to monitor evidence of cancer evolution.
  • RESULTS: Based on an analysis of EGFR in tumor specimens from 428 lung cancer patients, fifteen cases of sequential BAC-related adenocarcinoma obtained by thoracotomy were identified.
  • Together with alterations in BAC/adenocarcinoma components, the EGFR-TKI untreated series with at least one episode of EGFR-activating mutations represented three typical models: no significant EGFR evolution for a single clone, genetic alterations from mutant to wild-type EGFR for multifocal lesions, and a switch from wild-type to mutant EGFR, which might exhibit uncertain circumstances of cancer progression.
  • CONCLUSIONS: Genetic analysis in conjunction with pathological and radiological diagnoses can be used to explore the origin of multifocal BAC.
  • The single clone model indicates subsequent disease progression, whereas genetic alterations from mutations to wild-type EGFR are suggestive of secondary primary carcinoma.
  • When additional lesions emerge after radical resection of BAC-related lung cancer, sequential tumor samples should be obtained for further evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963232.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Morrison C, Gaile D, Darcy K, Liu S, Shepherd L, Cohn D, McMeekin S, Nowak N, Maxwell L: A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer.
  • RPCI 19K BAC arrays were hybridized (GeneTAC HybStation) and scanned (Gene Pix 4200AL Laser Scanner).
  • Validation will be performed by fluorescence in situ hybridization using select BAC probes and endometrial cancer tissue microarrays (TMAs) with either 400 cases linked with clinical, treatment and outcome data or 180 AA versus 120 C women from GOG-136.
  • Distinct genomic losses and gains were observed that appear to segregate Caucasian women with stage I disease from African American women with stage I disease and African American or Caucasian women with stage IIIC/IV disease.
  • Validation studies are currently underway in two endometrial cancer TMAs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ahmed S, Shahid RK: Acute interstitial pneumonitis following adjuvant tamoxifen therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11637

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e11637 Background: Tamoxifen is a serum estrogen receptor modulator that is widely used in the treatment of women with breast cancer and has a low incidence of serious side-effects.
  • Although hypersensitivity reactions to tamoxifen have rarely been described, to our knowledge acute lung toxicity has not previously been reported.
  • OBJECTIVE: To report an unusual case of acute interstitial pneumonitis in a patient with early stage breast cancer treated with tamoxifen.
  • An excision biopsy revealed 9 mm moderately differentiated invasive ductal carcinoma.
  • X-ray chest showed bilateral lung infiltrates.
  • Bronchoalveolar lavage was performed which was negative for infection.
  • An open lung biopsy was done which showed focal diffuse alveolar damage consistent with interstitial pneumonia.
  • She gradually recovered and was discharge to home with normal lung function.
  • CONCLUSIONS: Drug-induced lung injuries are usually idiosyncratic reactions and occur in an unpredictable manner.
  • The presence of a temporal relationship between the lung injury and tamoxifen administration, a rapid clinical improvement after discontinuation of the drug, and absence of other causes strongly implicated tamoxifen as a potential cause of acute lung injury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Quesenberry PJ, Del Tatto M, Berz D, Miner T, Ng T, Winer ES, Aliotta J, Colvin G, Dooner M, Dooner G, Fontaine JP: Marrow cell genetic phenotype change induced by human lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):11108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow cell genetic phenotype change induced by human lung cancer cells.
  • : 11108 Background: Murine lung-derived microvesicles are capable of inducing lung-specific mRNA in marrow cells, when co-cultured across from these cells, but separated from them by a cell-impermeable (0.4 micron) membrane.
  • These converted murine marrow cells showed mRNA elevations, lung-specific protein production and enhanced capacity to convert to lung epithelial cells after in vivo transplantation into irradiated mice.
  • We examine here whether fresh tissue from lung cancer patients would have the same capacity to genetically alter co-cultured human marrow cells.
  • METHODS: Lung cancer samples were collected from 5 patients undergoing surgery.
  • Marrow cell RNA was analyzed for lung specific mRNA using real time RT-PCR.
  • RESULTS: Lung cancers studied were adenocarcinoma, endobronchial alveolar carcinoma, bronchioloalveolar carcinoma, non-small cell carcinoma and squamous cell carcinoma. mRNAs for aquaporin 1-5, specific for type I pneumocytes and surfactant A-D, specific for type II pneumocytes, were measured.
  • Aquaporin I was elevated in marrow cells from co culture with all lung cancers; elevations ranging from 2.15 to 56.7 fold (mean 23 fold).
  • Similarly surfactant B mRNA was induced in marrow cells by all lung cancers with fold elevations ranging from 7.9 to 2164 (mean fold elevation 668).
  • CONCLUSIONS: These observations indicate that the genetic phenotype of cells in the vicinity of lung cancer cells can be altered and that these alterations might be mediated by microvesicle transfer of genetic information.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Goldberg J, Demetri GD, Choy E, Rosen L, Pappo A, Dubois S, Geller J, Chai F, Ferrari D, Wagner AJ: Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol; 2009 May 20;27(15_suppl):10502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10502 Background: ARQ 197 is a selective, non-ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.
  • The drug has demonstrated a favorable safety profile and preliminary anti-cancer activity in three phase 1 studies.
  • MiT tumors include clear cell sarcoma (CCS), alveolar soft part sarcoma (ASPS), and translocation-associated renal cell carcinoma (TLA RCC) and are linked biologically by a shared activated transcriptional mechanism which directly upregulates c-Met.
  • Tumors with this type of chromosomal abnormality are generally resistant to all approved therapies and, in the absence of complete surgical resection, prove invariably fatal.
  • One pt with CCS demonstrated a confirmed PR, 15 pts (10 ASPS, 2 CCS, 3 RCC) demonstrated stable disease (SD) for durations up to 29+ weeks, and 4 pts progressed.
  • An overall response rate of 5% and a disease control rate (CR+PR+SD) of 80% were demonstrated among 20 pts who were evaluable for efficacy.
  • CONCLUSIONS: To date, ARQ 197 has demonstrated an extremely favorable safety profile and preliminary evidence of anti-cancer activity in these young pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Groheux D, Hindié E, Trédaniel J, Giraudet AL, Vaylet F, Berenger N, Moretti JL: [PET-CT for evaluation of the solitary pulmonary nodule: an update]. Rev Mal Respir; 2009 Dec;26(10):1041-55
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • False negative results are mainly due to certain histological types with low metabolic activity (such as bronchiolo-alveolar carcinoma and typical carcinoid), or small size (nodules less than 8 mm).
  • [MeSH-major] Positron-Emission Tomography. Solitary Pulmonary Nodule / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032840.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 69
  •  go-up   go-down


32. Wang GF, Lai MD, Chen PH: [Correlation of multiple primary lung cancer with bronchial and alveolar epithelial dysplasia]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Sep;34(5):427-31
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of multiple primary lung cancer with bronchial and alveolar epithelial dysplasia].
  • OBJECTIVE: To investigate the correlation of multiple primary lung cancer with bronchial epithelial dysplasia and atypical adenomatous hyperplasia of bronchiolo-alveolar epithelium.
  • METHODS: Careful pathological examinations were performed on 114 surgical specimens of primary lung carcinoma.
  • The correlation of multiple primary lung cancer with bronchial epithelial dysplasia and atypical adenomatous hyperplasia of bronchiolo-alveolar epithelium was analyzed.
  • RESULTS: Of 114 cases of primary lung cancer,13 cases of multiple primary lung cancer (11.4 %) was identifiedìwhich consisted of 6 cases containing two primary bronchogenic carcinoma and 7 containing one bronchogenic carcinoma and one bronchiolo-alveolar carcinoma.
  • The rate of multiple primary lung cancers was significantly higher in individuals with high grade bronchial epithelial dysplasia than in those with low grade dysplasia (r=0.238, P<0.05).
  • CONCLUSION: Bronchial and alveolar epithelial cells may develop malignancy synchronously or metachronously.
  • The probability of developing multiple primary lung cancer will increase in the lungs with extensive and severe bronchial epithelial dysplasia.
  • [MeSH-major] Bronchi / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pulmonary Alveoli / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Male. Middle Aged. Precancerous Conditions / pathology. Respiratory Mucosa / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216054.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Barnoud R, Collardeau-Frachon S, de la Roche E, Vasiljevic A, Thomson V, Ranchère D, Devouassoux G, Devouassoux-Shisheboran M: [Lung metastases of epithelioid sarcoma revealed by bilateral spontaneous pneumothorax: a pathological diagnosis]. Ann Pathol; 2010 Apr;30(2):139-42
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung metastases of epithelioid sarcoma revealed by bilateral spontaneous pneumothorax: a pathological diagnosis].
  • We report the case of a 24-year-old man presenting a bilateral spontaneous pneumothorax in association with an epithelioid sarcoma developed in the right foot.
  • CT-scan revealed bilateral microcystic lesions with no evidence of metastatic disease.
  • Persistent air leakage led to a thoracotomy during which lung biopsies were carried out.
  • Histopathological examination of the pulmonary biopsies revealed rare millimetric nodules, composed of very atypical epithelioid cells, growing along alveolar walls reminiscent of a bronchiolo-alveolar carcinoma.
  • All these constatations allowed a diagnosis of pulmonary metastases of the epithelioid sarcoma.
  • [MeSH-major] Foot Diseases / pathology. Lung Neoplasms / secondary. Pneumothorax / etiology. Sarcoma / secondary


34. Knief P, Clarke C, Herzog E, Davoren M, Lyng FM, Meade AD, Byrne HJ: Raman spectroscopy--a potential platform for the rapid measurement of carbon nanotube-induced cytotoxicity. Analyst; 2009 Jun;134(6):1182-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study the suitability of Raman spectroscopy for the determination of carbon nanotube mediated toxicity on human alveolar carcinoma epithelial cells (A549) is explored.
  • The exposure of this cell line represents the primary pathway of exposure in humans, that of inhalation.
  • [MeSH-minor] Algorithms. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. Inhalation. Least-Squares Analysis. Multivariate Analysis. Principal Component Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475146.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nanotubes, Carbon
  •  go-up   go-down


35. Terzi A, Falezza G, Benato C, Genestreti G, Santo A, Furia S, Feil B, Calabrò F: Survival following complete resection of multifocal T4 node-negative NSCLC: a retrospective study. Thorac Cardiovasc Surg; 2007 Feb;55(1):44-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with multifocal pure bronchiolo-alveolar carcinoma were excluded.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality. Lymph Nodes / pathology. Pneumonectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285473.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Lee YC, Lee TH, Han HK, Go WJ, Yang JW, Shin HJ: Optical properties of fluorescein-labeled organoclay. Photochem Photobiol; 2010 May-Jun;86(3):520-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cellular uptake of FITC-organoclay in human lung alveolar carcinoma epithelial cells (A549) was quantified and characterized.
  • [MeSH-minor] Cell Line, Tumor. Humans. Lung Neoplasms / pathology. Nanoparticles / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158670.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Silicates; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


37. Herzog E, Casey A, Lyng FM, Chambers G, Byrne HJ, Davoren M: A new approach to the toxicity testing of carbon-based nanomaterials--the clonogenic assay. Toxicol Lett; 2007 Nov 1;174(1-3):49-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cellular toxicity of three types of carbon nanoparticles, namely HiPco single-walled carbon nanotubes (SWCNT), arc discharge SWCNT and Printex 90 carbon black nanoparticles, was studied on three different cell models including the human alveolar carcinoma epithelial cell line (A549), the normal human bronchial epithelial cell line (BEAS-2B) and the human keratinocyte cell line (HaCaT) using the clonogenic assay.
  • It could be shown that the toxicity of as produced SWCNT samples differs between cell lines and the SWCNT production method used, with HiPco SWCNT samples being more reactive compared to arc discharge produced SWCNT samples, both eliciting a stronger cytotoxic response than carbon black.
  • Furthermore, it was possible to distinguish between effects on cell viability and cell proliferation by including colony size as an additional endpoint in the clonogenic assay.
  • All three particle types were highly effective in inhibiting cell proliferation in all three cell lines, whereas only HaCaT and BEAS-2B cells also showed decreased cell viability.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Humans. Keratinocytes / cytology. Keratinocytes / drug effects. Respiratory Mucosa / cytology. Toxicity Tests / methods

  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920791.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nanotubes, Carbon; 7440-44-0 / Carbon
  •  go-up   go-down


38. Xu ML, Liu Y, Zhong HH, Wu BQ: [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):453-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung].
  • OBJECTIVE: To investigate mutations of epidermal growth factor receptor (EGFR) exon 19 and 21 in non-small cell lung carcinoma and to explore their clinicopathological correlations.
  • METHOD: DNA was extracted from the excised tumor specimens of 66 non-small cell lung carcinoma patients by traditional phenol-chloroform and ethanol precipitation.
  • Mutations were more frequently observed in women (9/34, 26.5%) than in men (2/32, 6.3%), in adenocarcinomas (10/43, 23.3%) than squamous (0/13) and adenosquamous carcinomas (1/10).
  • Those with adenocarcinoma with bronchiolo-alveolar carcinoma (BAC) components had higher frequency of EGFR mutation (6/11) than those without non-BAC element (4/32, 12.5%).
  • CONCLUSIONS: The mutations appear to occur in highly selected subgroups of lung cancer patients: adenocarcinomas with BAC components and patients of the female gender.
  • The results may offer practical approach to the rapid identification of lung cancer patients who likely respond to EGFR inhibitor therapy.
  • [MeSH-major] Amino Acid Substitution. Carcinoma, Non-Small-Cell Lung / genetics. Gene Deletion. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Female. Humans. Male. Middle Aged. Mutation. Sex Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845757.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


39. Mukohyama H, Haraguchi M, Sumita YI, Iida H, Hata Y, Kishimoto S, Taniguchi H: Rehabilitation of a bilateral maxillectomy patient with a free fibula osteocutaneous flap. J Oral Rehabil; 2005 Jul;32(7):541-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rehabilitation of a bilateral maxillectomy patient with a free fibula osteocutaneous flap.
  • A 58-year-old man with a maxillary alveolar carcinoma underwent bilateral maxillectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Fibula / transplantation. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Maxillofacial Prosthesis Implantation. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975135.001).
  • [ISSN] 0305-182X
  • [Journal-full-title] Journal of oral rehabilitation
  • [ISO-abbreviation] J Oral Rehabil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Jawa RS, Chattopadhyay S, Tracy E, Wang Y, Huntoon K, Dayton MT, Baumann H: Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages. J Interferon Cytokine Res; 2008 Apr;28(4):207-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages.
  • It is produced by activated T cells and signals via a heterodimeric receptor complex composed of IL-31Ralpha and OSMRbeta.
  • Only low levels of IL-31Ralpha expression have been demonstrated in pulmonary epithelial cell lines, however, and little is known about the ability to regulate its expression and signaling.
  • Therefore, primary cultures of human bronchial and alveolar epithelial cells, pulmonary fibroblasts, pulmonary macrophages, and established lines of immortalized bronchial epithelial cells (HBE) and alveolar carcinoma cells (A549) were analyzed by RT-PCR, immunoblotting, and thymidine incorporation.
  • Distinct, cell type-specific regulation of IL-31Ralpha expression was detected.
  • IL-31Ralpha protein expression was below detection threshold in primary epithelial cell cultures but was detectable in A549 cells and increased with TGF-beta treatment.
  • [MeSH-major] Bronchi / cytology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Regulation. Macrophages, Alveolar / metabolism. Pulmonary Alveoli / cytology. Receptors, Interleukin / metabolism
  • [MeSH-minor] Cell Proliferation / drug effects. Cells, Cultured. Culture Media, Conditioned. DNA / biosynthesis. Dexamethasone / pharmacology. Humans. Immunoblotting. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects. Transforming Growth Factor beta / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439099.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 085580; United States / NCI NIH HHS / CA / CA 16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / IL31RA protein, human; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Transforming Growth Factor beta; 7S5I7G3JQL / Dexamethasone; 9007-49-2 / DNA
  •  go-up   go-down


41. Gu AK, Sun LN, Chen ZL, Zhan ZL, Li JW: [Expression of coxsackievirus and adenovirus receptor in non-small cell lung cancer and its significance]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):278-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of coxsackievirus and adenovirus receptor in non-small cell lung cancer and its significance].
  • OBJECTIVE: To investigate the mRNA and proten expression of coxsackievirus and adenovirus receptor (CAR) in the corresponding normal lung tissue, para-neoplastic tissue and lung cancer tissue, and the correlation of CAR expression with the carcinogenesis as well as the expression difference in various clinicopathologic parameters.
  • METHODS: The expression of CAR mRNA and protein in the samples from 32 lung cancer patients was determined by RT-PCR and Western blot, respectively.
  • RESULTS: The expression level of CAR mRNA and protein in normal lung tissue, paraneoplastic tissue and cancer tissue were 1.000 +/- 0.012, 1.048 +/- 0.035, 1.282 +/- 0.072, and 0.902 +/- 0.038, 0.944 +/- 0.042, 1.08 +/- 0.052, respectively, with a statistical significance among the groups (P = 0.022, P = 0.007, P = 0.009, P = 0.027).
  • The expression levels of CAR were significantly different among different pathological types (P = 0.012), with a high level of CAR in all 7 bronchiolo-alveolar carcinoma (BAC, P = 0.029).
  • CONCLUSION: The expression of CAR mRNA and protein in cancer tissue samples are significantly higher than that in the normal and paraneoplastic samples, indicating that CAR might play a crucial role in the carcinogenesis.
  • It may become a new potential prognostic marker for lung cancer patients.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptors, Virus / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Coxsackie and Adenovirus Receptor-Like Membrane Protein. Female. Humans. Lung / metabolism. Lymphatic Metastasis. Male. Middle Aged. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLMP protein, human; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / RNA, Messenger; 0 / Receptors, Virus
  •  go-up   go-down


42. Mohr U, Ernst H, Roller M, Pott F: Pulmonary tumor types induced in Wistar rats of the so-called "19-dust study". Exp Toxicol Pathol; 2006 Aug;58(1):13-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of primary lung tumor types histologically diagnosed in 28 groups of Wistar rats of the so-called "19-dust study" are described, the total study having been already presented by Pott and Roller (Carcinogenicity study with nineteen granular dusts in rats.
  • In 579 (58%) lungs of 1002 rats which survived more than 26 weeks after the first instillation of GBP, at least one primary lung tumor type was observed, and in 306 (31%) at least two types.
  • Three benign tumor types were diagnosed in the 579 tumor-bearing rats: bronchiolo-alveolar adenoma in 46%, cystic keratinizing epithelioma in 53%, and non-keratinizing epithelioma in 2.6% of the rats.
  • Two of three malignant tumor types (bronchiolo-alveolar carcinoma and squamous cell carcinoma) occurred in 46% and 31% of the tumor-bearing rats, respectively, and adenosquamous carcinoma was diagnosed in 0.9%.
  • Numerous lungs with a malignant tumor also showed one or more benign tumor types.
  • In addition, single or multiple metastases from primary tumors of other sites (mainly carcinoma of the uterus) were diagnosed in 14% of the 1002 lungs.
  • [MeSH-major] Adenoma / chemically induced. Air Pollutants / toxicity. Carcinoma / chemically induced. Dust. Lung Neoplasms / chemically induced
  • [MeSH-minor] Aluminum Oxide / toxicity. Aluminum Silicates / toxicity. Animals. Carbon / toxicity. Carcinoma, Adenosquamous / chemically induced. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / pathology. Female. Intubation, Intratracheal. Particle Size. Rats. Rats, Wistar. Silicon Dioxide / toxicity. Specific Pathogen-Free Organisms. Titanium / toxicity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Aluminum oxide .
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Exp Toxicol Pathol. 2007 Aug;58(6):407; author reply 409 [17560773.001]
  • (PMID = 16806863.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Aluminum Silicates; 0 / Dust; 15FIX9V2JP / titanium dioxide; 7440-44-0 / Carbon; 7631-86-9 / Silicon Dioxide; D1JT611TNE / Titanium; LMI26O6933 / Aluminum Oxide
  •  go-up   go-down


43. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y, Ohkawa M: Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging; 2007 Oct;34(10):1610-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
  • PURPOSE: The nucleoside analogue 3'-deoxy-3'-(18)F-fluorothymidine (FLT) has recently been introduced for imaging cell proliferation with positron emission tomography (PET).
  • We prospectively evaluated whether FLT uptake reflects proliferative activity as indicated by the Ki-67 index in non-small cell lung cancer (NSCLC), in comparison with 2-deoxy-2-(18)F-fluoro-D-glucose (FDG).
  • RESULTS: The sensitivity of FLT and FDG PET for the detection of lung cancer was 72% and 89%, respectively.
  • Four of the five false-negative FLT PET findings occurred in bronchiolo-alveolar carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / metabolism. Dideoxynucleosides. Fluorodeoxyglucose F18. Ki-67 Antigen / blood. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):39-45 [9933660.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3331-4 [12067968.001]
  • [Cites] Gut. 2003 Nov;52(11):1602-6 [14570730.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 May;32(5):525-33 [15599526.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1677-82 [15471832.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):226-31 [14960640.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Nucl Med. 2000 Jan;41(1):85-92 [10647609.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1426-31 [12960187.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3837-44 [11051227.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):165-9 [11926377.001]
  • [Cites] Nucl Med Biol. 2000 Feb;27(2):143-56 [10773543.001]
  • [Cites] J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13 [1522276.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):400-4 [15750150.001]
  • [Cites] Chest. 2006 Feb;129(2):393-401 [16478857.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10 ):1407-12 [12898201.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):140-7 [16220306.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):882-6 [10750777.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3201-6 [10506619.001]
  • [Cites] J Nucl Med. 1984 Jul;25(7):759-64 [6610731.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2500-4 [11289121.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] Cancer. 2001 Aug 15;92 (4):886-95 [11550162.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1268-78 [12215569.001]
  • [Cites] Lung Cancer. 2002 Feb;35(2):179-87 [11804691.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):540-8 [12679397.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):914-9 [8611406.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4 [14991243.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • (PMID = 17530250.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Dideoxynucleosides; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


44. Lourenço R, Camacho R, Barata MJ, Canário D, Gaspar A, Cyrne C: CT-guided percutaneous transthoracic biopsy in the evaluation of undetermined pulmonary lesions. Rev Port Pneumol; 2006 Sep-Oct;12(5):503-24
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT-guided Percutaneous Transthoracic Biopsies (PTB) performed in the Radiology Department of Garcia de Orta Hospital between 2002 and 2004 to evaluate undetermined pulmonary lesions were retrospectively analysed.
  • 72 FNAB were considered adequate for cytology diagnosis; 72% of them positive for malignancy.
  • All malignant lesions were nodules: 20 adenocarcinoma, 13 non-small cell lung cancer (SCLC), 10 epidermoid tumours, 5 small-cell lung cancer, 2 carcinoids, 1 bronchiolo alveolar carcinoma, 1 malignant mesothelioma and 8 metastasis.
  • Malignant lesions were more prevalent in older patients (p=0.007) and were larger (p=0.006).
  • Spiculated and lobulated contour (p=0.05) were more prevalent in malignant lesions while regular contour was more frequent among benign lesions (p=0.0001).
  • Gender, smoking, location, pleural tag, homogenous attenuation, cavitation, calcification, necrosis and air bronchogram did not differ significantly between benign and malignant nodules.
  • [MeSH-major] Biopsy, Needle / methods. Lung Diseases / diagnosis. Lung Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117322.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


45. Reymann S, Borlak J: Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst Biol; 2008;2:46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network.
  • Targeted overexpression of this gene in mice results in distinct types of lung adenocarcinomas.
  • By using microarray technology, alterations in the expression of genes were captured based on a female transgenic mouse model in which, indeed, c-Myc overexpression in alveolar epithelium results in the development of bronchiolo-alveolar carcinoma (BAC) and papillary adenocarcinoma (PLAC).
  • In this study, we analyzed exclusively the promoters of induced genes by different in silico methods in order to elucidate the c-Myc transcriptional regulatory network.
  • CONCLUSION: Our in silico data suggest a model of a transcriptional regulatory network in which different TFs act in concert upon c-Myc overexpression.
  • We determined molecular rules for transcriptional regulation to explain, in part, the carcinogenic effect seen in mice overexpressing the c-Myc oncogene.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / metabolism. Models, Biological. Proto-Oncogene Proteins c-myc / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5313-8 [12702757.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3576-9 [12824369.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1211-7 [2006410.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Cell Growth Differ. 1992 Mar;3(3):183-90 [1633109.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3237-47 [8344261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 [8356088.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 11;21(16):3767-75 [8367294.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):5083-7 [8262051.001]
  • [Cites] Genes Dev. 1994 Jul 1;8(13):1526-37 [7958837.001]
  • [Cites] Science. 1995 Jan 20;267(5196):389-93 [7824938.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1536-44 [7862146.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1508-19 [7729426.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16503-8 [8845379.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1101-11 [8548798.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4878-84 [8532532.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10750-8 [16322220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9 [17093053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18580-5 [17132729.001]
  • [Cites] Nucleic Acids Res. 2007;35(4):1098-107 [17264126.001]
  • [Cites] PLoS Comput Biol. 2007 Apr 6;3(4):e63 [17411336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9375-88 [14645547.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2546-59 [14993291.001]
  • [Cites] J Cell Biochem. 2004 Apr 1;91(5):896-903 [15034925.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3459-71 [15213251.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6740-9 [15374992.001]
  • [Cites] Nucleic Acids Res. 2004;32(17):4955-61 [15388797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(10):3594-8 [2524830.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5 [10737792.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Prostate. 2000 Jun 1;43(4):278-85 [10861747.001]
  • [Cites] Adv Cancer Res. 1996;68:109-82 [8712067.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):573-8 [8761372.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 15;25(6):1108-16 [9092617.001]
  • [Cites] Diabetes. 1998 Jan;47(1):98-103 [9421381.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):668-74 [9618270.001]
  • [Cites] Dev Biol. 1998 Oct 15;202(2):183-95 [9769171.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:103-25 [10331078.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2916-24 [10378688.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2925-33 [10378689.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):216-21 [10381369.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):521-35 [15546613.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):336-46 [15616584.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):382-90 [15778709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6902-6 [15867157.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2590-601 [15990869.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5490-502 [10891489.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3200-12 [10918575.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):281-3 [11125113.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):28-34 [11018030.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 15;29(2):397-406 [11139609.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L695-704 [11238010.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1383-93 [11250904.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4984-94 [11526483.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8116-24 [11781825.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 15;29(24):4994-5000 [11812829.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11617-20 [11805123.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):513-26 [11973610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9 [11983876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Development. 2002 Jun;129(11):2723-32 [12015299.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G266-9 [12121872.001]
  • [Cites] J Neurooncol. 2002 May;57(3):201-14 [12125983.001]
  • [Cites] Hum Mol Genet. 2002 Aug 1;11(16):1817-21 [12140184.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):166-74 [12185365.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):36921-30 [12145275.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1315-23 [12368205.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7877-88 [12391156.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8300-8 [12501251.001]
  • (PMID = 18498649.001).
  • [ISSN] 1752-0509
  • [Journal-full-title] BMC systems biology
  • [ISO-abbreviation] BMC Syst Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2430022
  •  go-up   go-down


46. Wang T, Sun YE, Yao SL, Yu CH, Yin DY, Tian JH: [Value of carbon-11 choline positron emission tomography in patients with pulmonary abnormalities]. Zhonghua Wai Ke Za Zhi; 2006 Mar 15;44(6):405-8
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the value of carbon-11 choline (CH) positron emission tomography (PET) in patients with pulmonary nodules.
  • METHODS: From September 2002 to December 2004, 39 patients with pulmonary nodules were imaged with CH-PET.
  • CH-PET data was analyzed by visual method and semiquantitative method.
  • When pulmonary nodules with abnormal CH uptake appeared in PET scans confirmed by visual method, their maximum and mean standard uptake value (SUVmax and SUVmean) were measured using semiquantitative method.
  • RESULTS: Twenty-four cancerous and 3 inflammatory nodules and 1 bronchogenic cyst were detected by CH-PET and were diagnosed malignant with visual method.
  • Three bronchial alveolar carcinoma, 2 metastatic tumor from kidney and colon, 3 fibrous nodules, 1 cryptococcosis, 1 hamartoma and 1 sclerosing hemangioma showed nothing abnormal in PET scans.
  • For identification of pulmonary nodules with CH-PET, the sensitivity was 89% (24/29), the specificity was 60% (6/10), and the accuracy was 77% (30/39).
  • There were differences in SUV between 8 squamous cell carcinomas and 9 adenocarcinomas (Z = -2.937, -2.887, P < 0.01).
  • In diagnosing 70 resected enlarged lymph nodes beyond 1 cm in 17 lung cancer patients, CH-PET had the sensitivity of 86% (25/29), the specificity of 90% (37/41), and the accuracy of 89% (62/70).
  • CH-PET confirmed 7 distant metastases in 25 lung cancer patients.
  • In 5 cases suspected brain metastases CH-PET identified 2 cases positive correctly.
  • CONCLUSIONS: CH-PET can confirm malignant pulmonary nodules, but still there were false positive and false negative cases.
  • CH-PET can evaluate N stage effectively in patients with lung cancer.
  • CH-PET can depict brain metastases accurately.
  • [MeSH-major] Lung / radionuclide imaging. Lung Diseases / diagnosis. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638358.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; N91BDP6H0X / Choline
  •  go-up   go-down


47. Zhang GZ, Jiao SC, Meng ZT: Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res; 2010;29:38
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
  • BACKGROUND: The objective of this study was to evaluate the efficacy and safety of pemetrexed plus cisplatin/carboplatin in locally advanced or metastatic non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy.
  • METHODS: Fifty-three locally advanced or metastatic non-small cell lung cancer patients previously treated with platinum-based chemotherapy received pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin area under the curve (AUC) 5 every 21 days, with dexamethasone, folic acid and vitamin B12 being administered.
  • Thirty-seven patients had adenocarcinoma (including 6 alveolar carcinoma patients), and fourteen patients had squamous cell carcinoma.
  • Seven patients (13.2%) showed partial response; Thirty-six (67.9%) had stable disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Glutamates / administration & dosage. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy


48. Tamura K, Fukuoka M: Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother; 2005 Jun;6(6):985-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib in non-small cell lung cancer.
  • Gefitinib (Iressa), an orally-active tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), is the first approved molecular-targeted drug for the management of patients with advanced non-small cell lung cancer (NSCLC).
  • Two Phase II trials (IDEAL [Iressa Dose Evaluation in Advanced Lung Cancer]-1 and -2), evaluated the efficacy of gefitinib in advanced NSCLC patients who received < or = 2 (IDEAL1) or > or = 2 (IDEAL2) previous chemotherapy regimens.
  • The response rate and disease control rate in IDEAL1 and -2 was 18/12% and 54/42%, respectively.
  • Furthermore, in a recent randomised, placebo-controlled, Phase III trial (ISEL: IRESSA Survival Evaluation in Lung cancer), gefitinib failed to prolong survival compared with placebo in patients with advanced NSCLC who had failed one or more lines of chemotherapy.
  • In addition, subset analyses of IDEAL and several retrospective studies have indicated that female gender, adenocarcinoma histology (especially bronchial alveolar carcinoma), non-smoker status and Asian ethnicity are factors which predict to response to gefitinib.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952926.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  • [Number-of-references] 52
  •  go-up   go-down


49. Figiel S, de Leval L, Rousié C, Duysinx B, Louis R, Defraigne JO, Radermecker M: [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma]. Rev Med Liege; 2010 Nov;65(11):611-4
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma].
  • [Transliterated title] Le cas clinique du mois. La triade "classique" de présentation de certains cancers bronchiolo-alvéolaires mucineux.
  • The case of a 59-year-old female complaining of cough of recent onset, abundant salty expectoration and lung condensation is presented.
  • This "triad" constitutes a rare but nearly pathognomonic presentation of mucinous bronchioloalveolar carcinoma (BAC) of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Cough / etiology. Female. Humans. Lung / pathology. Lung / radiography. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189525.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


50. Heyer CM, Kagel T, Lemburg SP, Walter JW, de Zeeuw J, Junker K, Mueller KM, Nicolas V, Bauer TT: Transbronchial biopsy guided by low-dose MDCT: a new approach for assessment of solitary pulmonary nodules. AJR Am J Roentgenol; 2006 Oct;187(4):933-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: We included 33 consecutive patients (25 men; mean age +/- SD, 64 +/- 9.6 years) with solitary pulmonary nodules at different sites and with a lesion-to-pleura distance of at least 2 cm who previously underwent conventional bronchoscopy that did not result in histologic diagnosis.
  • RESULTS: The diagnostic yield was 24 in 33 selected patients (overall accuracy, 72.7%): 13 (54%) had primary lung cancer and 11 (46%) had benign diagnoses.
  • The final diagnoses of the remaining nine patients in whom transbronchial bronchoscopic biopsy was not diagnostic were non-small cell lung cancer (n = 3); small cell lung cancer (n = 3); and alveolar carcinoma, carcinoid tumor, and hemorrhaged bulla (n = 1 each).
  • [MeSH-major] Biopsy, Needle / methods. Lung / pathology. Lung Neoplasms / diagnosis. Radiography, Interventional. Solitary Pulmonary Nodule / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985137.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Lorusso V, Gebbia V, Spada M, Guida M, Cassano G, Brunetti C, Germano D, Nettis G, Izzi G, Galetta D, Giampaglia M, Silvestris N, Colucci G: Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncol Rep; 2005 Dec;14(6):1547-51
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
  • A number of second line treatments have been proposed in patients with advanced pretreated non-small cell lung cancer (NSCLC).
  • The median age was 63 years (range 43-76); cell types were: squamous carcinoma (n=17), adenocarcinoma (n=16), large cell carcinoma (n=3), broncho-alveolar carcinoma (n=2) and undifferentiated carcinoma (n=4).
  • Median time to disease progression and median survival were 9 weeks (range 1-13) and 26 weeks (range 1-91+), respectively.
  • Combination of topotecan and ifosfamide demonstrated antitumor activity in patients with relapsing or refractory NCSLC with a modest side effect profile and an overall disease control (PR + MR + SD) of 50.7%.
  • Nevertheless, the still low response rate and the shortness of median survival indicates the need for more effective second line treatments in this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


52. Fisher DR, Weller RE: Carcinogenesis from inhaled (239)PuO(2) in beagles: Evidence for radiation homeostasis at low doses? Health Phys; 2010 Sep;99(3):357-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Years later, the purpose of the present follow-up study was to reassess the dose-response relationship for lung cancer in the PuO(2) dogs compared to controls-with particular focus on the dose-response at relatively low lung doses.
  • In dose level 1, initial pulmonary lung depositions were 130 + or - 48 Bq (3.5 + or - 1.3 nCi), corresponding to 1 Bq g lung tissue (0.029 + or - 0.001 nCi g(-1)).
  • Groups 2 through 6 received initial lung depositions (mean values) of 760, 2,724, 10,345, 37,900, and 200,000 Bq (22, 79, 300, 1,100, and 5,800 nCi) PuO(2), respectively.
  • For each dog, the absorbed dose to lungs was calculated from the initial lung burden and the final lung burden at time of death and lung mass, assuming a single, long-term retention function.
  • Increased dose-dependent mortality due to lung cancer (bronchiolar-alveolar carcinoma, adenocarcinoma, and epidermoid carcinoma) and radiation pneumonitis (in the highest exposure group) were observed in dogs exposed to PuO(2).
  • Calculated lung doses ranged from a few cGy (lowest exposure level) to 7,764 cGy in dogs that experienced early deaths from radiation pneumonitis.
  • Data were regrouped by lifetime lung dose and plotted as a function of lung tumor incidence.
  • The lung tumor incidence in controls and zero-dose exposed dogs was 18% (5/28).
  • However, no lung tumors were observed in 16 dogs with the lowest lung doses (8 to 22 cGy, mean 14.4 + or - 7.6 cGy), and only one lung tumor was observed in the next 10 dogs with lung doses ranging from 27 to 48 cGy (mean 37.5 + or - 10.9 cGy).
  • However, the incidence of lung tumors at zero dose was significantly greater than the incidence at low dose (at the p < or = 0.053 confidence level), suggesting a protective effect (radiation homeostasis) of alpha-particle radiation from PuO(2).
  • If a threshold for lung cancer incidence exists, it will be observed in the range 15 to 40 cGy.
  • [MeSH-major] Aerosols / toxicity. Carcinogens / toxicity. Homeostasis / radiation effects. Lung Neoplasms / chemically induced. Neoplasms, Radiation-Induced / chemically induced. Plutonium / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Health Phys. 2012 Mar;102(3):348-50; author reply 350-1 [22315023.001]
  • [CommentIn] Health Phys. 2012 Mar;102(3):346-7 [22420023.001]
  • (PMID = 20699697.001).
  • [ISSN] 1538-5159
  • [Journal-full-title] Health physics
  • [ISO-abbreviation] Health Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Carcinogens; 12059-95-9 / plutonium dioxide; 53023GN24M / Plutonium
  •  go-up   go-down


53. Nag S, Saraswathi TR, Sekhar G, Einstein A, Sivapathasundharam B: A rare case of sarcoid-like reaction of lymph nodes associated with squamous cell carcinoma of alveolar mucosa. Indian J Dent Res; 2009 Oct-Dec;20(4):503-5
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of sarcoid-like reaction of lymph nodes associated with squamous cell carcinoma of alveolar mucosa.
  • Non-necrotizing granulomas are occasionally seen in patients with certain malignant disorders and are termed as "sarcoid-like reaction," which have many similarities with sarcoidosis.
  • Sarcoidosis is a multisystem granulomatous disease of unknown etiology characterized by organ involvement and interference of organ function by granuloma or fibrosis.
  • Sarcoidosis is occasionally found in a variety of malignant diseases with an overall incidence of 4.4% in carcinoma patients.
  • We present here a rare case of moderately differentiated squamous cell carcinoma of alveolar mucosa with regard to mandible associated with sarcoid-like reaction of cervical lymph nodes in a female patient in the absence of clinical evidence of systemic sarcoidosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lymphatic Diseases / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Sarcoidosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139581.001).
  • [ISSN] 1998-3603
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 10
  •  go-up   go-down


54. Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK: BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. J Thorac Oncol; 2006 Nov;1(9 Suppl):S2-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.
  • INTRODUCTION: Human bronchioloalveolar carcinoma (BAC) is a disease with an evolving definition.
  • "Pure" BAC, characterized by a bronchioloalveolar growth pattern and no evidence of stromal, vascular, or pleural invasion, represents only 2 to 6% of non-small cell lung cancer (NSCLC) cases, but up to 20% of NSCLC cases may contain elements of BAC.
  • However, because BAC appears to behave clinically differently from adenocarcinoma, a better understanding of this disease entity is imperative.
  • METHODS/RESULTS: At the BAC Consensus Conference in 2004, our committee discussed issues relevant to BAC epidemiology, pathogenesis, and preclinical models.
  • CONCLUSIONS: Elucidation of molecular events involved in BAC tumorigenesis will allow for more precise epidemiologic studies and improved animal models, which will enable development of more effective treatments against the disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / epidemiology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / epidemiology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Animals. Biopsy, Needle. Diagnosis, Differential. Disease Models, Animal. Female. Humans. Immunohistochemistry. Male. Mice. Mice, Nude. Mice, Transgenic. Neoplasm Staging. Prevalence. Prognosis. Risk Assessment. Sheep

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2007 Jan;2(1):11. Kim, Kwok [corrected to Wong, Kwok-Kin]
  • (PMID = 17409996.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 074386; United States / NCI NIH HHS / CA / CA 092824; United States / NCI NIH HHS / CA / CA 0940578; United States / NCI NIH HHS / CA / CA 59116; United States / NIA NIH HHS / AG / K08AG 2400401
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


55. Guard O: [BAC 40 battery: a tool of cognitive evaluation for the diagnosis of Alzheimer's disease at the specialist office]. Rev Neurol (Paris); 2010 Jun-Jul;166(6-7):615-20
MedlinePlus Health Information. consumer health - Alzheimer's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BAC 40 battery: a tool of cognitive evaluation for the diagnosis of Alzheimer's disease at the specialist office].
  • [Transliterated title] La batterie BAC 40: un outil d'évaluation cognitive pour le diagnostic de la maladie d'Alzheimer au cabinet du spécialiste.
  • BAC 40 is a "composite" battery of psychometric tests useful for the diagnosis of Alzheimer's dementia.
  • The advantage is to establish a diagnosis in less than 20 minutes, exploring all the sectors of cognitive life.
  • The scores obtained with "BAC 40" and the "ADAS-COG SCALE" were compared in all patients.
  • [MeSH-major] Alzheimer Disease / diagnosis. Neuropsychological Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149920.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Validation Studies
  • [Publication-country] France
  •  go-up   go-down


56. Kim TH, Kim SJ, Ryu YH, Chung SY, Seo JS, Kim YJ, Choi BW, Lee SH, Cho SH: Differential CT features of infectious pneumonia versus bronchioloalveolar carcinoma (BAC) mimicking pneumonia. Eur Radiol; 2006 Aug;16(8):1763-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential CT features of infectious pneumonia versus bronchioloalveolar carcinoma (BAC) mimicking pneumonia.
  • The purpose of this study was to evaluate retrospectively the differential CT features of bronchioloalveolar carcinoma (BAC) mimicking pneumonia and infectious pneumonia at the lung periphery.
  • CT images were reviewed in 47 patients with focal areas of parenchymal opacification at the lung periphery.
  • We evaluated the presence of ground-glass attenuation, marginal conspicuity of the lesion, CT angiogram sign, air-bronchogram sign, a bubble-like low-attenuation area within the lesion, presence of pleural thickening and retraction associated with the lesion, presence of pleural effusion and extra-pleural fatty hypertrophy, presence of bronchial wall thickening proximal to the lesion, and air-trapping in the normal lung near the lesion.
  • BAC (n=18) depicted the presence of a bubble-like low-attenuation area within the lesion, whereas infectious pneumonia (n=29) represented the pleural thickening associated with the lesion and bronchial wall thickening proximal to the lesion (P<0.05).
  • The focal areas of the parenchymal opacification on the CT images may suggest infectious pneumonia rather than BAC when they show bronchial wall thickening proximal to the lesion and pleural thickening associated with the lesion, whereas BAC is characterized as the presence of a bubble-like low attenuation area within the tumor.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Lung Neoplasms / diagnostic imaging. Pneumonia / diagnostic imaging. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Female. Humans. Iohexol / analogs & derivatives. Male. Middle Aged. Predictive Value of Tests. Radiography, Thoracic. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1984 Jan;150(1):15-20 [6316417.001]
  • [Cites] Radiology. 1991 May;179(2):469-76 [2014294.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jun;127(6):1574-8 [15173709.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):525-34 [6329505.001]
  • [Cites] Radiology. 1992 Nov;185(2):401-5 [1329140.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):275-7 [1321558.001]
  • [Cites] J Thorac Imaging. 1995 Spring;10 (2):96-8 [7769637.001]
  • [Cites] Eur Radiol. 1998;8(6):996-1001 [9683709.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):609-12 [8392527.001]
  • [Cites] Arch Ophthalmol. 1993 Dec;111(12):1627-34 [8155032.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Eur Radiol. 2005 Oct;15(10 ):2075-8 [15717197.001]
  • [Cites] Radiology. 1996 May;199(2):485-8 [8668800.001]
  • [Cites] Adv Anat Pathol. 2005 Jan;12(1):1-6 [15614158.001]
  • [Cites] Radiology. 1990 Sep;176(3):749-53 [2167502.001]
  • [Cites] Eur Radiol. 1999;9(1):55-9 [9933380.001]
  • [Cites] Adv Intern Med. 1960;10:329-58 [13762021.001]
  • [Cites] Cancer. 1972 Oct;30(4):1107-18 [4342854.001]
  • [Cites] Radiology. 1988 May;167(2):379-82 [2833764.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):133-5 [9022785.001]
  • [Cites] Chest Surg Clin N Am. 1994 Aug;4(3):405-30 [7953476.001]
  • [Cites] J Thorac Imaging. 1994 Summer;9(3):141-4 [8083927.001]
  • [Cites] J Thorac Imaging. 1995 Spring;10 (2):106-11 [7769623.001]
  • [Cites] Radiol Clin North Am. 1990 May;28(3):583-97 [2158119.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1163-70 [8313318.001]
  • [Cites] Semin Roentgenol. 1990 Jan;25(1):105-11 [2157287.001]
  • [Cites] Am J Clin Pathol. 1999 Dec;112(6):777-83 [10587700.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):319-26 [14644520.001]
  • (PMID = 16418864.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


57. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M: Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol; 2005 May 10;23(14):3279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.
  • PURPOSE: To review recent advances in pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC).
  • METHODS: A pathology/CT review panel of pathologists and radiologists met during a November 2004 International Association for the Study of Lung Cancer/American Society of Clinical Oncology consensus workshop in New York.
  • The purpose was to determine if existing data was sufficient to propose modification of criteria for adenocarcinoma and BAC as newly published in the 2004 WHO Classification of Lung Tumors, and to address the pathologic/radiologic concept of diffuse/multicentric BAC.
  • RESULTS: Solitary small, peripheral BACs have an excellent prognosis.
  • Most lung adenocarcinomas with a BAC pattern are not pure BAC, but rather adenocarcinoma, mixed subtype with invasive patterns.
  • The percent of BAC versus invasive components in lung adenocarcinomas appears to be prognostically important.
  • However, a consensus definition of "minimally invasive" BAC with a favorable prognosis could not be achieved.
  • While recognition of a BAC component is possible, the diagnosis of BAC with exclusion of invasive adenocarcinoma cannot be made by small biopsy or cytology specimens.
  • CONCLUSION: There is a need to work toward a mutual understanding and consensus between pathologists, clinicians, and researchers with the use of the term BAC versus adenocarcinoma.
  • Hopefully, this work will allow definition of a category of adenocarcinoma, mixed subtype with predominant BAC/minimal invasion and a favorable prognosis.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886315.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


58. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, Matsuo K, Otani H, Jida M, Kubo T, Tsukuda K, Kiura K, Sano Y, Date H: Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol; 2008 Jul;3(7):704-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
  • OBJECTIVE: The purpose of this study was to identify risk factors for poor clinical outcome after surgical resection of small lung adenocarcinoma.
  • MATERIALS AND METHODS: Clinical records of 127 patients who had pathologic stage IA lung adenocarcinoma 20 mm or less and who had undergone a lobectomy with mediastinal lymph node dissection were reviewed.
  • The percentage of non-bronchioloalveolar carcinoma (non-BAC) components quantified objectively, and epidermal growth factor receptor gene (EGFR) mutation determined by polymerase chain reaction-based assay were retrospectively linked with clinical data.
  • RESULTS: Based on the percentage of non-BAC component, 127 patients were classified as follows: 26 in group I, BAC, 46 in group II mixed subtype with >or= 50% BAC, 18 in group III, mixed subtype with under 50% BAC, and 37 in group IV, mixed subtype with all non-BAC components or a pure pattern of one of the non-BAC components.
  • Groups I and II were considered to be a "low non-BAC component type" and groups III and IV were considered to be a "high non-BAC component type."
  • In terms of recurrence, the high non-BAC component type was the only independent factor for recurrence (p = 0.029).
  • Regarding survival, the high age (p = 0.028) and high non-BAC component type (p = 0.046) were independent risk factors for poor overall survival.
  • They were also independent risk factors for poor disease-free survival (p = 0.025 and p = 0.027, respectively).
  • CONCLUSION: The high non-BAC component but not EGFR mutation status, is an independent risk factor for both recurrence and poor prognosis in patients with stage IA lung adenocarcinoma <or=20 mm.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology. Mutation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Wislez M, Antoine M, Rabbe N, Gounant V, Poulot V, Lavolé A, Fleury-Feith J, Cadranel J: Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res; 2007 Jun 15;13(12):3518-27
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features.
  • PURPOSE: Adenocarcinoma with bronchioloalveolar carcinoma (BAC) features is a subtype of non-small cell lung cancers characterized by an intense inflammatory reaction composed of macrophages and neutrophils and by a distinct natural history with intrapulmonary spread leading to death due to respiratory failure.
  • We hypothesized that neutrophils could promote aerogenous spread of lung adenocarcinoma with BAC features.
  • EXPERIMENTAL DESIGN: We examined the effect of neutrophils on A549 cell line detachment in vitro and we quantified desquamation of tumor cells on tumor tissue (n = 25) and on matched bronchioloalveolar lavage (n = 17) in vivo in a series of patients with adenocarcinoma with BAC features.
  • RESULTS: Neutrophils induced A549 detachment mediated by signals through cell-to-cell contact.
  • Neutralization studies identified several membrane-bound molecules involved in detachment (i.e., intercellular adhesion molecule-1/lymphocyte function-associated antigen-1, tumor necrosis factor alpha/tumor necrosis factor alpha receptor inhibitor, interleukin-1alpha /interleukin-1alpha receptor, and neutrophil elastase).
  • The micropapillary score was associated with a high neutrophil count in bronchioloalveolar lavage (P = 0.051).
  • The shedding cell percentage was a significant factor in shorter survival (P = 0.034, univariate Cox analysis).
  • It is a significant factor of shorter survival and may be an important event in adenocarcinoma progression.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology. Neoplasm Invasiveness / pathology. Neutrophils / metabolism
  • [MeSH-minor] Cell Adhesion / physiology. Cell Communication / physiology. Cell Line, Tumor. Cell Proliferation. Coculture Techniques. Female. Flow Cytometry. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575214.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Jeong Y, Epstein DJ: Modification and production of BAC transgenes. Curr Protoc Mol Biol; 2005 Aug;Chapter 23:Unit 23.11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modification and production of BAC transgenes.
  • Bacterial artificial chromosomes (BACs) are the vectors of choice for the construction of genomic DNA libraries and, as such, have proven instrumental in the generation of large-scale physical maps; positional cloning projects; and the sequencing of human, mouse, and a plethora of other genomes.
  • A number of methods have recently been developed to modify BAC DNA (e.g., insertion, deletion, substitution), making BACs even more useful for functional genomic research.
  • This unit describes two protocols for BAC modification in E. coli, one that allows for specific changes at a given DNA sequence and another that is more suited for rapid and nonspecific integration of foreign DNA (such as a reporter cassette) into a BAC insert.
  • In addition, a simple and reliable method for preparing BAC DNA for pronuclear microinjection is also provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265362.001).
  • [ISSN] 1934-3647
  • [Journal-full-title] Current protocols in molecular biology
  • [ISO-abbreviation] Curr Protoc Mol Biol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Transposable Elements
  •  go-up   go-down


61. Prabhu S, Smitha RS, Punnya VA: Merkel cell carcinoma of the alveolar mucosa in a young adult: a rare case report. Br J Oral Maxillofac Surg; 2010 Jan;48(1):48-50
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the alveolar mucosa in a young adult: a rare case report.
  • Merkel cell carcinoma (MCC) is an extremely rare and aggressive primary neuroendocrine neoplasm of the skin with a poor prognosis.
  • We report a rare case of MCC that arose in the alveolar mucosa of a young adult.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Alveolar Process / pathology. Chromogranins / analysis. Follow-Up Studies. Humans. Keratin-3 / analysis. Lymphatic Metastasis / pathology. Male. Mouth Floor / pathology. Oral Ulcer / pathology. Radiography, Panoramic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19167791.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Chromogranins; 0 / KRT3 protein, human; 0 / Keratin-3
  •  go-up   go-down


62. Coe BP, Lockwood WW, Chari R, Lam WL: Comparative genomic hybridization on BAC arrays. Methods Mol Biol; 2009;556:7-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization on BAC arrays.
  • Alterations in genomic DNA are a key feature of many constitutional disorders and cancer.
  • The discovery of the underlying regions of gene dosage has thus been essential in dissecting complex disease phenotypes and identifying targets for therapeutic intervention and diagnostic testing.
  • The development of array comparative genomic hybridization (aCGH) using bacterial artificial chromosomes (BACs) as hybridization targets has facilitated the discovery and fine mapping of novel genomic alterations allowing rapid identification of target genes.
  • In BAC aCGH, DNA samples are first labeled with fluorescent dyes through a random priming reaction with 100-400 ng of genomic DNA.
  • This probe is then co-hybridized to an array consisting of BAC clones, either tiling the genome (approximately 50 kbp resolution) or spaced at intervals (e.g., 1 Mbp resolution).
  • The DNA samples to be analyzed may be derived from either fresh, frozen, or formalin-fixed paraffin-embedded material, and sample requirements are currently significantly lower than those for oligonucleotide platforms due to the high probe-binding capacity of BAC clone targets (approximately 150 kbp) compared to oligonucleotides (25-80 bp).
  • In this chapter, we describe in detail the technical procedure required to perform copy number analysis of genomes with BAC aCGH.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. Comparative Genomic Hybridization. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488868.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE15965
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Osoegawa K, Vessere GM, Li Shu C, Hoskins RA, Abad JP, de Pablos B, Villasante A, de Jong PJ: BAC clones generated from sheared DNA. Genomics; 2007 Feb;89(2):291-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC clones generated from sheared DNA.
  • BAC libraries generated from restriction-digested genomic DNA display representational bias and lack some sequences.
  • To facilitate completion of genome projects, procedures have been developed to create BACs from DNA physically sheared to create fragments extending up to 200 kb.
  • The DNA fragments were repaired to create blunt ends and ligated to a new BAC vector.
  • This approach has been tested by generating BAC libraries from Drosophila DNA with insert lengths between 50 and 150 kb.
  • The libraries lack chimeric clone problems as determined by mapping paired BAC-end sequences to the assembled fly genome sequence.
  • The utility of "sheared" libraries was demonstrated by closure of a previous clone gap and by isolation of clones from telomeric regions, which were notably absent from previous Drosophila BAC libraries.

  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Evol. 1999 Oct;16(10):1341-6 [10563015.001]
  • [Cites] Nat Rev Genet. 2002 Feb;3(2):91-102 [11836503.001]
  • [Cites] Science. 2000 Mar 24;287(5461):2271-4 [10731150.001]
  • [Cites] Chromosome Res. 2000;8(7):651-3 [11117362.001]
  • [Cites] Mol Gen Genet. 2000 Nov;264(4):371-7 [11129040.001]
  • [Cites] Nature. 2002 Aug 15;418(6899):743-50 [12181558.001]
  • [Cites] Nature. 2002 Oct 3;419(6906):498-511 [12368864.001]
  • [Cites] Genome Biol. 2002;3(12):RESEARCH0079 [12537568.001]
  • [Cites] Genome Biol. 2002;3(12):RESEARCH0085 [12537574.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36005-12 [12840022.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):493-521 [15057822.001]
  • [Cites] Genome Res. 2004 Apr;14(4):766-79 [15060021.001]
  • [Cites] Genome Res. 2004 Apr;14(4):780-5 [15060022.001]
  • [Cites] Mol Biol Evol. 2004 Sep;21(9):1613-9 [15163766.001]
  • [Cites] Mol Biol Evol. 2004 Sep;21(9):1620-4 [15175413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Feb;83(3):696-700 [3080746.001]
  • [Cites] Science. 1986 Dec 19;234(4783):1582-5 [3538420.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(16):6240-4 [2668959.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4663-7 [1584802.001]
  • [Cites] Genetics. 1993 May;134(1):293-308 [8514138.001]
  • [Cites] Genetics. 1994 Jul;137(3):803-13 [7916308.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):934-41 [11237014.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):948-51 [11237019.001]
  • [Cites] Genome Res. 2001 Mar;11(3):483-96 [11230172.001]
  • [Cites] Genome Res. 2001 May;11(5):710-30 [11337470.001]
  • [Cites] Genomics. 1996 Jun 1;34(2):213-8 [8661051.001]
  • [Cites] Chromosome Res. 1996 Aug;4(5):372-83 [8871826.001]
  • [Cites] Nucleic Acids Res. 1997 Oct 1;25(19):3959-61 [9380525.001]
  • [Cites] Genomics. 1998 Aug 15;52(1):1-8 [9740665.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 15;27(16):3318-24 [10454639.001]
  • [Cites] Chromosoma. 2004 Dec;113(6):295-304 [15616866.001]
  • [Cites] Nature. 2005 May 5;435(7038):43-57 [15875012.001]
  • [Cites] Genomics. 2001 Sep;77(1-2):27-34 [11543629.001]
  • [Cites] Genome Res. 2000 Jan;10(1):116-28 [10645956.001]
  • (PMID = 17098394.001).
  • [ISSN] 0888-7543
  • [Journal-full-title] Genomics
  • [ISO-abbreviation] Genomics
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / HG000750-07; United States / NHGRI NIH HHS / HG / HG00750; United States / NHGRI NIH HHS / HG / P50 HG000750-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS16521; NLM/ PMC1909752
  •  go-up   go-down


64. Suster ML, Sumiyama K, Kawakami K: Transposon-mediated BAC transgenesis in zebrafish and mice. BMC Genomics; 2009;10:477
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transposon-mediated BAC transgenesis in zebrafish and mice.
  • BACKGROUND: Bacterial artificial chromosomes (BACs) are among the most widely used tools for studies of gene regulation and function in model vertebrates, yet methods for predictable delivery of BAC transgenes to the genome are currently limited.
  • This is because BAC transgenes are usually microinjected as naked DNA into fertilized eggs and are known to integrate as multi-copy concatamers in the genome.
  • Although conventional methods for BAC transgenesis have been very fruitful, complementary methods for generating single copy BAC integrations would be desirable for many applications.
  • RESULTS: We took advantage of the precise cut-and-paste behavior of a natural transposon, Tol2, to develop a new method for BAC transgenesis.
  • In this new method, the minimal sequences of the Tol2 transposon were used to deliver precisely single copies of a approximately 70 kb BAC transgene to the zebrafish and mouse genomes.
  • We mapped the BAC insertion sites in the genome by standard PCR methods and confirmed transposase-mediated integrations.
  • CONCLUSION: The Tol2 transposon has a surprisingly large cargo capacity that can be harnessed for BAC transgenesis.
  • The precise delivery of single-copy BAC transgenes by Tol2 represents a useful complement to conventional BAC transgenesis, and could aid greatly in the production of transgenic fish and mice for genomics projects, especially those in which single-copy integrations are desired.
  • [MeSH-major] Chromosomes, Artificial, Bacterial. DNA Transposable Elements. Gene Transfer Techniques. Zebrafish / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transgenic Res. 2001 Apr;10(2):83-103 [11305364.001]
  • [Cites] Nat Rev Neurosci. 2001 Dec;2(12):861-70 [11733793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4495-9 [11904379.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):443-7 [12627172.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):133-44 [15239961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jul;82(13):4438-42 [3892534.001]
  • [Cites] Nature. 1986 Oct 2-8;323(6087):445-8 [3762693.001]
  • [Cites] Transgenic Res. 1997 Jan;6(1):3-10 [9032972.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):56-9 [9425901.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):15-6 [10471489.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):e36 [15731329.001]
  • [Cites] Mol Reprod Dev. 2005 Nov;72(3):329-35 [16047391.001]
  • [Cites] Methods. 2006 Jul;39(3):183-8 [16828309.001]
  • [Cites] Genetics. 2006 Oct;174(2):639-49 [16959904.001]
  • [Cites] Mamm Genome. 2007 Oct;18(10):693-708 [17882484.001]
  • [Cites] Genome Biol. 2007;8 Suppl 1:S13 [18047690.001]
  • [Cites] Genome Biol. 2007;8 Suppl 1:S7 [18047699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1255-60 [18202183.001]
  • [Cites] Methods Mol Biol. 2008;415:83-100 [18370149.001]
  • [Cites] Dev Biol. 2009 Jan 15;325(2):422-33 [18992237.001]
  • [Cites] Transgenic Res. 2009 Oct;18(5):769-85 [19396621.001]
  • (PMID = 19832998.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Transposable Elements
  • [Other-IDs] NLM/ PMC2768751
  •  go-up   go-down


65. Todesco S, Campagna D, Levorin F, D'Angelo M, Schiavon R, Valle G, Vezzi A: PABS: an online platform to assist BAC-by-BAC sequencing projects. Biotechniques; 2008 Jan;44(1):60, 62, 64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PABS: an online platform to assist BAC-by-BAC sequencing projects.
  • Genome sequencing projects are either based on whole genome shotgun (WGS) or on a BAC-by-BAC strategy.
  • Although WGS is in most cases the preferred choice, sometimes the BAC-by-BAC approach may be better because it requires a much simpler assembly process.
  • Furthermore, when the study is limited to specific regions of the genome, the WGS would require an unjustified effort, making the BAC-by-BAC the only feasible strategy.
  • In this paper we describe an informatics pipeline called PABS (Platform Assisted BAC-by-BAC Sequencing) that we developed to provide a tool to optimize the BAC-by-BAC sequencing strategy.
  • PABS has two main functions: (i) PABS-Select, to choose suitable overlapping clones; and (ii) PABS-Validate, to verify whether a BAC under analysis is actually overlapping the neighboring BAC.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. Computational Biology / methods. Internet. Sequence Analysis, DNA / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254380.001).
  • [ISSN] 0736-6205
  • [Journal-full-title] BioTechniques
  • [ISO-abbreviation] BioTechniques
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Lysak MA, Mandáková T, Lacombe E: Reciprocal and multi-species chromosome BAC painting in crucifers (Brassicaceae). Cytogenet Genome Res; 2010 Jul;129(1-3):184-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reciprocal and multi-species chromosome BAC painting in crucifers (Brassicaceae).
  • In crucifer cytogenomics, BAC contigs of Arabidopsis thaliana have been used as probes for comparative chromosome painting among species.
  • Here we successfully tested chromosome-specific BAC contigs of A. thaliana (n = 5) and A. halleri (n = 8) as probes for reciprocal BAC painting.
  • Furthermore, BAC contigs of both Arabidopsis species were applied as multi-species painting probes to a third crucifer species, Noccaea caerulescens (n = 7), revealing their shared chromosome homeology.
  • [MeSH-major] Brassicaceae / genetics. Chromosome Painting / methods. Chromosomes, Artificial, Bacterial / genetics. Chromosomes, Plant / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20501976.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Madishetty K, Condamine P, Svensson JT, Rodriguez E, Close TJ: An improved method to identify BAC clones using pooled overgos. Nucleic Acids Res; 2007;35(1):e5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An improved method to identify BAC clones using pooled overgos.
  • Hybridization using overgo probes is an established approach for screening arrayed bacterial artificial chromosome (BAC) libraries.
  • The resulting cost savings and reduced human exposure to radiation make the use of highly pooled overgo probes a more attractive approach for screening of BAC libraries from organisms with large genomes.
  • [MeSH-major] Chromosomes, Artificial, Bacterial. Genomic Library. Oligonucleotide Probes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2000 May;10(5):714-21 [10810094.001]
  • [Cites] BMC Bioinformatics. 2006;7:7 [16401345.001]
  • [Cites] Curr Opin Plant Biol. 2002 Apr;5(2):173-7 [11856615.001]
  • [Cites] Plant Cell. 2002 Mar;14(3):537-45 [11910002.001]
  • [Cites] Genome Res. 2002 May;12(5):795-807 [11997346.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1277-85 [12176935.001]
  • [Cites] Theor Appl Genet. 2003 Aug;107(4):652-60 [12783166.001]
  • [Cites] Genome Res. 2003 Dec;13(12):2754-8 [14656976.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2118-20 [14684821.001]
  • [Cites] Cytogenet Genome Res. 2003;102(1-4):277-81 [14970717.001]
  • [Cites] Plant Physiol. 2004 Apr;134(4):1317-26 [15020742.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3230-42 [15322185.001]
  • [Cites] Plant J. 2004 Nov;40(4):500-11 [15500466.001]
  • [Cites] Genetics. 2004 Oct;168(2):1087-96 [15514080.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5661-6 [9576940.001]
  • [Cites] Genomics. 1998 Dec 15;54(3):387-97 [9878241.001]
  • [Cites] Genome Res. 2005 Jan;15(1):166-73 [15590945.001]
  • [Cites] PLoS Biol. 2005 Jan;3(1):e13 [15660154.001]
  • [Cites] Funct Integr Genomics. 2005 Apr;5(2):97-103 [15666175.001]
  • [Cites] Bioessays. 2005 Aug;27(8):839-48 [16015589.001]
  • [Cites] Theor Appl Genet. 2005 Aug;111(3):467-78 [15965650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13206-11 [16141333.001]
  • [Cites] Genome Res. 2005 Oct;15(10):1441-6 [16204197.001]
  • [Cites] Mol Genet Genomics. 2005 Oct;274(3):248-63 [16179993.001]
  • [Cites] Theor Appl Genet. 2005 Nov;111(8):1596-607 [16200416.001]
  • [Cites] Genome Res. 2000 Jun;10(6):789-807 [10854411.001]
  • (PMID = 17151072.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotide Probes; 0 / Radioisotopes
  • [Other-IDs] NLM/ PMC1761434
  •  go-up   go-down


68. Kong LY, Zhang XJ, Wang ZS: [Removal of organic pollutants by adsorption cooperated with biodegradation in BAC]. Huan Jing Ke Xue; 2007 Apr;28(4):777-80
Hazardous Substances Data Bank. ACTIVATED CHARCOAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Removal of organic pollutants by adsorption cooperated with biodegradation in BAC].
  • The determination measure for distribution of NOM removal by two mechanisms in BAC was established.
  • In this method, the change in DOC and BDOC of inflow and effluent was used to evaluate the distribution and to determinate the effect of the different ozone doses on the adsorption and biodegradation in BAC.
  • The ozonation increased the concentration of BDOC in 0.12 - 0.54 mg/L with ozone dose of 2 - 8 mg/L and BAC filtration decreased concentration of BDOC to 0.23 - 0.31 mg/L.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639936.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organic Chemicals; 0 / Water Pollutants, Chemical; 16291-96-6 / Charcoal
  •  go-up   go-down


69. Ren ZJ, Ma J, Cao XC: [Effect of PPC preoxidation on BAC process for removing organic matters]. Huan Jing Ke Xue; 2006 Oct;27(10):2045-9
Hazardous Substances Data Bank. POTASSIUM PERMANGANATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of PPC preoxidation on BAC process for removing organic matters].
  • The effect of PPC preoxidation on BAC process for organic pollutants removal was conducted by measuring the distribution of relative molecular mass, the concentrations of organic and inorganic matters on BAC.
  • On the other hand, organic matters of relative molecular mass less than 3 x 10(3) is increased with PPC preoxidation, which improves the biological activity of BAC process.
  • The concentrations of organic and inorganic matters on BAC with PPC preoxidation are reduced 5.0 mg x g(-1) and 4.16 mg x g(-1) respectively than that on BAC alone, which reduces the block of hole on GAC and increases the life time of BAC process.

  • Hazardous Substances Data Bank. ACTIVATED CHARCOAL .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256607.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organic Chemicals; 0 / Water Pollutants, Chemical; 00OT1QX5U4 / Potassium Permanganate; 16291-96-6 / Charcoal; 7440-44-0 / Carbon
  •  go-up   go-down


70. Jenkins G, Hasterok R: BAC 'landing' on chromosomes of Brachypodium distachyon for comparative genome alignment. Nat Protoc; 2007;2(1):88-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC 'landing' on chromosomes of Brachypodium distachyon for comparative genome alignment.
  • Fluorescence in situ hybridization (FISH) using bacterial artificial chromosomes (BACs) with large genomic DNA inserts as probes (BAC 'landing') is a powerful means by which eukaryotic genomes can be physically mapped and compared.
  • Here we report a BAC landing protocol that has been developed specifically for the weedy grass species Brachypodium distachyon, which has been adopted recently by the scientific community as an alternative model for the temperate cereals and grasses.
  • The protocol describes the preparation of somatic and meiotic chromosome substrates for FISH, the labeling of BACs, a chromosome mapping strategy, empirical conditions for optimal in situ hybridization and stringency washing, the detection of probes and the capturing and processing of images.
  • The expected outcome of the protocol is the specific assignment of BACs containing single-copy inserts to one of the five linkage groups of the genome of this species.
  • [MeSH-major] Chromosome Mapping / methods. Chromosomes, Artificial, Bacterial / genetics. Genetic Techniques. Genome, Plant / genetics. Poaceae / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17401342.001).
  • [ISSN] 1750-2799
  • [Journal-full-title] Nature protocols
  • [ISO-abbreviation] Nat Protoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


71. Zhong M, De Angelo P, Osborne L, Keane-Tarchichi M, Goldfischer M, Edelmann L, Yang Y, Linehan WM, Merino MJ, Aisner S, Hameed M: Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol; 2010 Jun;34(6):757-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.
  • Both Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS) are characterized by various translocations disrupting chromosome Xp11.2, which result in gene fusions involving the TFE3 transcription factor gene.
  • This assay was validated using 4 cases of Xp11.2 RCC [proven by karyotype and/or reverse-transcriptase polymerase chain reaction (RT-PCR)], 2 cases of ASPS (proven by karyotype or RT-PCR), the UOK109 cell line carrying the inv(X) (p11;q12), and several negative controls (both neoplastic and non-neoplastic).
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, X / genetics. In Situ Hybridization, Fluorescence / methods. Kidney Neoplasms / genetics. Sarcoma, Alveolar Soft Part / genetics

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421778.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / TFE3 protein, human
  •  go-up   go-down


72. Parchem RJ, Poulin F, Stuart AB, Amemiya CT, Patel NH: BAC library for the amphipod crustacean, Parhyale hawaiensis. Genomics; 2010 May;95(5):261-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC library for the amphipod crustacean, Parhyale hawaiensis.
  • Bacterial artificial chromosomes (BACs) are capable of propagating large fragments of DNA and have become an invaluable tool for studying genome biology.
  • To fill a phylogenetic gap in available genomic sequence and to complement ongoing molecular and genetic studies, we have generated a BAC library for the marine amphipod crustacean, Parhyale hawaiensis.
  • We have screened the Parhyale BAC library for developmentally relevant genes and characterized the genomic organization of four genes: a hedgehog ortholog, and three Pax3/7 paralogs.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. Crustacea / genetics. Genomic Library. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20298775.001).
  • [ISSN] 1089-8646
  • [Journal-full-title] Genomics
  • [ISO-abbreviation] Genomics
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


73. Gorman DM, Huber JC Jr, Carozza SE: Evaluation of the Texas 0.08 BAC law. Alcohol Alcohol; 2006 Mar-Apr;41(2):193-9
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the Texas 0.08 BAC law.
  • AIMS: The purpose of the present study was to assess the effects on alcohol-involved traffic crashes and fatalities of the 0.08 blood alcohol concentration (BAC) per se law introduced in the state of Texas in 1999.
  • CONCLUSIONS: While there is a growing body of evidence that indicates that 0.08 BAC laws can be effective in reducing alcohol-involved traffic accidents and fatalities, the present study shows that this was not the case in Texas.
  • Future research should move beyond the simple question of whether or not 0.08 BAC laws 'work' and instead explore in more detail the conditions, such as publicity and enforcement, under which the law does or does not contribute to a decline in alcohol-involved accidents and fatalities.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364969.001).
  • [ISSN] 0735-0414
  • [Journal-full-title] Alcohol and alcoholism (Oxford, Oxfordshire)
  • [ISO-abbreviation] Alcohol Alcohol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


74. Yang XW, Gong S: An overview on the generation of BAC transgenic mice for neuroscience research. Curr Protoc Neurosci; 2005 May;Chapter 5:Unit 5.20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview on the generation of BAC transgenic mice for neuroscience research.
  • This unit provides a comprehensive overview on the generation of transgenic mice using bacterial artificial chromosomes (BACs), and the application of BAC transgenic mice in neuroscience research.
  • In the first section, advantages of the BAC transgenic approach compared to the conventional transgenic approach are summarized.
  • In the second section, important considerations in designing BAC transgenic constructs are outlined.
  • Four commonly used BAC transgenic construct designs are also outlined.
  • Concepts of modifying BACs by homologous recombination in E. coli to introduce a variety of mutations into BACs, and important steps to characterize a modified BAC prior to the generation of transgenic mice are also presented.
  • In the final section, some of the important applications of BAC transgenic mice in neuroscience research, including studying gene expression, gene function, mapping neuronal circuitry, and modeling human diseases, are described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18428622.001).
  • [ISSN] 1934-8576
  • [Journal-full-title] Current protocols in neuroscience
  • [ISO-abbreviation] Curr Protoc Neurosci
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Escherichia coli Proteins
  • [Number-of-references] 31
  •  go-up   go-down


75. Roohi J, Cammer M, Montagna C, Hatchwell E: An improved method for generating BAC DNA suitable for FISH. Cytogenet Genome Res; 2008;121(1):7-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An improved method for generating BAC DNA suitable for FISH.
  • These probes are often generated from DNA sequences cloned within bacterial artificial chromosomes (BACs).
  • Growing these BACs in adequate amounts for FISH can be demanding.
  • We describe FISH performed with bacteriophage Phi29 DNA polymerase amplified BAC DNA.
  • The FISH results obtained were comparable with those obtained from standard BAC DNA.
  • We believe this method of BAC DNA generation is useful for the entire FISH community as it improves considerably on prior methods.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. DNA, Recombinant / biosynthesis. DNA, Recombinant / genetics. In Situ Hybridization, Fluorescence / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18544919.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Recombinant; EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.1.- / SEPT9 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


76. Sazanov AA, Malewski T, Kamiński S, Zwierzchowski L: Characterization of the CHORI-240 BAC clones containing the bovine CSN1S1, CSN2, STATH, CSN1S2 and CSN3 genes. J Appl Genet; 2006;47(3):243-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the CHORI-240 BAC clones containing the bovine CSN1S1, CSN2, STATH, CSN1S2 and CSN3 genes.
  • Nineteen BAC clones were identified by hybridization of the bovine genomic BAC library CHORI-240 with mixed CSN1S1- and CSN3-specific probes.
  • These data showed that the BAC contig was established for the whole casein cluster, including all known five genes.
  • [MeSH-major] Caseins / genetics. Cattle / genetics. Chromosomes, Artificial, Bacterial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 1999 Oct;15(10):403-8 [10498936.001]
  • [Cites] Genomics. 2003 Oct;82(4):417-32 [13679022.001]
  • [Cites] Mamm Genome. 1997 Feb;8(2):148-52 [9060418.001]
  • [Cites] Mamm Genome. 1997 Apr;8(4):285-6 [9096114.001]
  • (PMID = 16877803.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caseins; 0 / DNA Primers
  •  go-up   go-down


77. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG: Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res; 2005;33(4):e36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simple and highly efficient BAC recombineering using galK selection.
  • Here, we describe the construction of three new recombineering strains (SW102, SW105 and SW106) that allow bacterial artificial chromosomes (BACs) to be modified using galK positive/negative selection.
  • We also show how galK selection can be used to rapidly introduce point mutations, deletions and loxP sites into BAC DNA and thus facilitate functional studies of SNP and/or disease-causing point mutations, the identification of long-range regulatory elements and the construction of conditional targeting vectors.
  • [MeSH-major] Chromosomes, Artificial, Bacterial. Escherichia coli / genetics. Escherichia coli Proteins / genetics. Galactokinase / genetics. Genetic Engineering. Recombination, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5978-83 [10811905.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1555-7 [10037821.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Nat Rev Genet. 2001 Oct;2(10):769-79 [11584293.001]
  • [Cites] Annu Rev Genet. 2002;36:361-88 [12429697.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1992-8 [12466304.001]
  • [Cites] Genome Res. 2003 Mar;13(3):476-84 [12618378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7207-12 [12771385.001]
  • [Cites] Genomics. 2003 Jul;82(1):68-77 [12809677.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2190-4 [12915491.001]
  • [Cites] Virology. 2004 Feb 20;319(2):185-9 [14980479.001]
  • [Cites] J Bacteriol. 1975 Jan;121(1):259-66 [1090571.001]
  • [Cites] Nucleic Acids Res. 1986 Mar 11;14(5):2287-300 [3457367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4645-9 [2162051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7 [1528894.001]
  • [Cites] Cell. 1997 May 16;89(4):655-67 [9160756.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):859-65 [9306400.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):123-8 [9771703.001]
  • [Cites] Genesis. 2001 Jan;29(1):14-21 [11135458.001]
  • (PMID = 15731329.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Escherichia coli Proteins; EC 2.7.1.6 / Galactokinase; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC549575
  •  go-up   go-down


78. Kong LY, Zhang XJ, Wang ZS: [Determination for optimal ozone dose in O3-BAC]. Huan Jing Ke Xue; 2006 Jul;27(7):1345-7
Hazardous Substances Data Bank. ACTIVATED CHARCOAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Determination for optimal ozone dose in O3-BAC].
  • In the test, the AOC of effluent from BAC is lower than 50 microg/L (acetate-C).

  • MedlinePlus Health Information. consumer health - Ozone.
  • Hazardous Substances Data Bank. OZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16881306.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Water Pollutants; 16291-96-6 / Charcoal; 66H7ZZK23N / Ozone
  •  go-up   go-down


79. Park MH, Lee HJ, Bok J, Kim CH, Hong ST, Park C, Kimm K, Oh B, Lee JY: Korean BAC library construction and characterization of HLA-DRA, HLA-DRB3. J Biochem Mol Biol; 2006 Jul 31;39(4):418-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Korean BAC library construction and characterization of HLA-DRA, HLA-DRB3.
  • A human bacterial artificial chromosome (BAC) library was constructed with high molecular weight DNA extracted from the blood of a male Korean.
  • This Korean BAC library contains 100,224 clones of insert size ranging from 70 to 150 kb, with an average size of 86 kb, corresponding to a 2.9-fold redundancy of the genome.
  • The average insert size was determined from 288 randomly selected BAC clones that were well distributed among all the chromosomes.
  • We developed a pooling system and three-step PCR screen for the Korean BAC library to isolate desired BAC clones, and we confirmed its utility using primer pairs designed for one of the clones.
  • The Korean BAC library and screening pools will allow PCR-based screening of the Korean genome for any gene of interest.
  • The haplotype found in this library will provide useful information in future human disease studies.
  • [MeSH-minor] Asian Continental Ancestry Group. Chromosomes, Artificial, Bacterial. HLA-DR alpha-Chains. HLA-DRB3 Chains. Haplotypes. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889686.001).
  • [ISSN] 1225-8687
  • [Journal-full-title] Journal of biochemistry and molecular biology
  • [ISO-abbreviation] J. Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / HLA-DR alpha-Chains; 0 / HLA-DRB3 Chains
  •  go-up   go-down


80. Ching TT, Maunakea AK, Jun P, Hong C, Zardo G, Pinkel D, Albertson DG, Fridlyand J, Mao JH, Shchors K, Weiss WA, Costello JF: Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet; 2005 Jun;37(6):645-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3.
  • We developed a method for high-resolution analysis of the methylation status of CpG islands genome-wide, using arrays of BAC clones and the methylation-sensitive restriction enzyme NotI.
  • [MeSH-major] Carrier Proteins / metabolism. Chromosomes, Artificial, Bacterial. CpG Islands. DNA Methylation

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895082.001).
  • [ISSN] 1061-4036
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nerve Tissue Proteins; 0 / SHANK3 protein, human; EC 3.1.21.- / endodeoxyribonuclease BSSHII; EC 3.1.21.4 / Deoxyribonucleases, Type II Site-Specific; EC 3.1.21.4 / GCGGCCGC-specific type II deoxyribonucleases
  •  go-up   go-down


81. Jiang S, Zhong X, Zhai C, Chen L, Ma L, Jin M, Chen H: Constructing recombinant herpesvirus BAC vectors with mating-assisted genetically integrated clone method. Biotechnol Lett; 2010 Jul;32(7):903-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constructing recombinant herpesvirus BAC vectors with mating-assisted genetically integrated clone method.
  • Here we introduced a cloning strategy that facilitates construction of recombinant PRV-BAC vectors based on mating-assisted genetically integrated clone (MAGIC).
  • The target gene was cloned into a small conditionally replicating donor plasmid, followed by shuffling to a recipient PRV-BAC plasmid in vivo of Escherichia coli through MAGIC.
  • [MeSH-major] Chromosomes, Artificial, Bacterial. Gene Targeting / methods. Genetic Engineering / methods. Genetic Vectors. Herpesvirus 1, Suid / genetics. Recombination, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349331.001).
  • [ISSN] 1573-6776
  • [Journal-full-title] Biotechnology letters
  • [ISO-abbreviation] Biotechnol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


82. Schemerhorn BJ, Crane YM, Morton PK, Aggarwal R, Benatti T: Localization and characterization of 170 BAC-derived clones and mapping of 94 microsatellites in the Hessian fly. J Hered; 2009 Nov-Dec;100(6):790-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization and characterization of 170 BAC-derived clones and mapping of 94 microsatellites in the Hessian fly.
  • Ninety-four microsatellites from enriched genomic libraries of Hessian fly (Hf, Mayetiola destructor [Say]) were localized to 170 cognate clones in an Hf bacterial artificial chromosome (BAC) library.
  • These microsatellite-positive BAC clones were physically mapped to polytene chromosomes by fluorescent in situ hybridization.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. Diptera / genetics. Gene Library. Genetic Variation. Genetics, Population. Microsatellite Repeats / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592640.001).
  • [ISSN] 1465-7333
  • [Journal-full-title] The Journal of heredity
  • [ISO-abbreviation] J. Hered.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


83. Zhang ZH, Shao L: Study on control of micro-pollutants by BAC filtration. Water Sci Technol; 2008;58(3):677-82
Hazardous Substances Data Bank. ACTIVATED CHARCOAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study on control of micro-pollutants by BAC filtration.
  • The objective of this research was to evaluate removal efficiency of micro-pollutants in a BAC filter that followed ozonation for long term operation.
  • The experimental results showed that after continuous operation for one year BAC filter still maintained a removal of 15 approximately 20% for COD(Mn) and 20 approximately 30% of removal for UV(254).
  • Correlative analysis based on lots of data found that empty bed contact time (EBCT) instead of flow rate could obviously impact on removal effect of micro-pollutants in BAC filter.
  • And the optimal relationship between EBCT and removal effect of micro-pollutants for BAC filter was logarithm.
  • On the other hand, long term running of BAC filter proved that there was a good removal of chloroform formation potential, but the removal of brominated trihalomethane formation potential decline with further bromization, even there appeared to be formation of bromoform in BAC filter.

  • Hazardous Substances Data Bank. OZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) IWA Publishing 2008.
  • (PMID = 18725738.001).
  • [ISSN] 0273-1223
  • [Journal-full-title] Water science and technology : a journal of the International Association on Water Pollution Research
  • [ISO-abbreviation] Water Sci. Technol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Trihalomethanes; 0 / Water Pollutants, Chemical; 16291-96-6 / Charcoal; 66H7ZZK23N / Ozone
  •  go-up   go-down


84. Shoguchi E, Kawashima T, Satou Y, Hamaguchi M, Sin-I T, Kohara Y, Putnam N, Rokhsar DS, Satoh N: Chromosomal mapping of 170 BAC clones in the ascidian Ciona intestinalis. Genome Res; 2006 Feb;16(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal mapping of 170 BAC clones in the ascidian Ciona intestinalis.
  • Here, we report the molecular cytogenetic characterization of all 14 pairs of C. intestinalis chromosomes, as well as initial large-scale mapping of genomic sequences onto chromosomes by fluorescent in situ hybridization (FISH).
  • Two-color FISH using 170 bacterial artificial chromosome (BAC) clones and construction of joined scaffolds using paired BAC end sequences allowed for mapping of up to 65% of the deduced 117-Mb nonrepetitive sequence onto chromosomes.
  • [MeSH-minor] Animals. Chromosomes, Artificial, Bacterial / genetics. Gene Expression Regulation / genetics. In Situ Hybridization, Fluorescence / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4469-74 [10781046.001]
  • [Cites] Methods Mol Biol. 2000;132:185-219 [10547837.001]
  • [Cites] Int Rev Cytol. 2002;217:227-76 [12019564.001]
  • [Cites] Genesis. 2002 Aug;33(4):153-4 [12203911.001]
  • [Cites] Genes Genet Syst. 2002 Aug;77(4):283-5 [12419901.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2157-67 [12481130.001]
  • [Cites] Nat Rev Genet. 2003 Apr;4(4):285-95 [12671659.001]
  • [Cites] Zoolog Sci. 2004 Feb;21(2):153-7 [14993826.001]
  • [Cites] PLoS Biol. 2003 Nov;1(2):E45 [14624247.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):361-6 [8401583.001]
  • [Cites] Genome Res. 2004 Dec;14(12):2448-56 [15545496.001]
  • [Cites] Dev Biol. 2004 Dec 15;276(2):563-80 [15581886.001]
  • [Cites] Genome Res. 2005 Jan;15(1):1-18 [15632085.001]
  • [Cites] Genome Res. 2005 Aug;15(8):1127-35 [16077012.001]
  • [Cites] Int Rev Cytol. 2001;203:3-62 [11131520.001]
  • (PMID = 16354750.001).
  • [ISSN] 1088-9051
  • [Journal-full-title] Genome research
  • [ISO-abbreviation] Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1361726
  •  go-up   go-down


85. Wagenaar AC, Maldonado-Molina MM, Ma L, Tobler AL, Komro KA: Effects of legal BAC limits on fatal crash involvement: analyses of 28 states from 1976 through 2002. J Safety Res; 2007;38(5):493-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of legal BAC limits on fatal crash involvement: analyses of 28 states from 1976 through 2002.
  • We examined the effects of changes in legal BAC limit in 28 U.S. states from January, 1976 to December, 2002.
  • Four outcome measures of alcohol-related crash involvement were examined: single-vehicle nighttime, BAC=0.01-0.07, BAC=0.08-0.14, and BAC>/=0.15.
  • Missing BAC test result data were handled by using multiple imputations.
  • Inverse variance weighting methods were used to pool results across states for the most precise underlying estimate of effect of legal BAC limits.
  • Changes in legal BAC limits significantly affected alcohol-related fatal crash involvement for both the SVN and BAC test result measures, and the laws affected drivers at all drinking levels.
  • IMPACT ON INDUSTRY: Given the significant effects of lower legal BAC limits on fatal crash involvement, businesses should support implementation of laws that further reduce the legal BAC limit for all drivers.
  • Furthermore, all companies should set higher standards for employees, such as a zero allowable BAC limit for driving during work time.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023634.001).
  • [ISSN] 0022-4375
  • [Journal-full-title] Journal of safety research
  • [ISO-abbreviation] J Safety Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Moraes AP, Mirkov TE, Guerra M: Mapping the chromosomes of Poncirus trifoliata Raf. by BAC-FISH. Cytogenet Genome Res; 2008;121(3-4):277-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mapping the chromosomes of Poncirus trifoliata Raf. by BAC-FISH.
  • In order to obtain a better chromosome characterization of one species from this group, CMA/DAPI double staining followed by in situ hybridization using 45S rDNA and 24 BACs (BAC-FISH) were used on Poncirus trifoliata.
  • The BACs used were obtained from a genomic library of this species and were selected by membrane hybridization using genomic DNA.
  • The P. trifoliata karyotype is composed of two chromosome pairs with one terminal and one proximal CMA(+) band (B type chromosomes), four chromosome pairs with a single CMA(+) band (D type) and three chromosome pairs without bands (F type).
  • In situ hybridization with 13 of the BACs gave single copy signals on seven chromosome pairs.
  • At least one BAC was mapped on each arm of the two B chromosome pairs.
  • Among the four D chromosome pairs, two were identified by BACs mapped on the long arms, one has a 45S rDNA site and the other had no signal.
  • Six BACs allowed identification of the three F chromosome pairs, with one pair hybridizing with four BACs from the Ctv resistance gene region.
  • In summary, all nine chromosome pairs could be differentiated, seven of them by BAC-FISH, while the other two chromosomes could be recognized by the CMA(+) band pattern and 45S rDNA sites.
  • This first BAC-FISH map gives a general framework for comparative genome structure and evolutionary studies in Citrus and Poncirus, allowing the integration of genetic and physical maps when these BACs are included.
  • [MeSH-major] Chromosome Mapping. Chromosomes, Artificial, Bacterial. Chromosomes, Plant. In Situ Hybridization, Fluorescence / methods. Poncirus / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18758171.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Ribosomal
  •  go-up   go-down


87. Neill NJ, Torchia BS, Bejjani BA, Shaffer LG, Ballif BC: Comparative analysis of copy number detection by whole-genome BAC and oligonucleotide array CGH. Mol Cytogenet; 2010;3:11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of copy number detection by whole-genome BAC and oligonucleotide array CGH.
  • It has been presumed that whole-genome oligonucleotide (oligo) arrays identify more clinically significant copy-number abnormalities than whole-genome bacterial artificial chromosome (BAC) arrays, yet this has not been systematically studied in a clinical diagnostic setting.
  • RESULTS: To determine the difference in detection rate between similarly designed BAC and oligo arrays, we developed whole-genome BAC and oligonucleotide microarrays and validated them in a side-by-side comparison of 466 consecutive clinical specimens submitted to our laboratory for aCGH.
  • Of the 466 cases studied, 67 (14.3%) had a copy-number imbalance of potential clinical significance detectable by the whole-genome BAC array, and 73 (15.6%) had a copy-number imbalance of potential clinical significance detectable by the whole-genome oligo array.
  • However, because both platforms identified copy number variants of unclear clinical significance, we designed a systematic method for the interpretation of copy number alterations and tested an additional 3,443 cases by BAC array and 3,096 cases by oligo array.
  • Of those cases tested on the BAC array, 17.6% were found to have a copy-number abnormality of potential clinical significance, whereas the detection rate increased to 22.5% for the cases tested by oligo array.
  • CONCLUSIONS: Although BAC arrays have faster turnaround times, the increased detection rate of oligo arrays makes them attractive for clinical cytogenetic testing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2010 May 14;86(5):749-64 [20466091.001]
  • [Cites] Curr Opin Pediatr. 2005 Dec;17(6):740-6 [16282780.001]
  • [Cites] Mol Cytogenet. 2009;2:17 [19664229.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1377-83 [19193630.001]
  • [Cites] Cytogenet Genome Res. 2008;123(1-4):234-43 [19287160.001]
  • [Cites] Hum Mutat. 2009 Feb;30(2):135-44 [18837009.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1466-71 [19029900.001]
  • [Cites] Clin Genet. 2008 Nov;74(5):469-75 [18811697.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1685-99 [18784092.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1101-8 [18361433.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):33-44 [14685263.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):863-8 [11509994.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):437-44 [10679223.001]
  • [Cites] Nature. 2008 Sep 11;455(7210):232-6 [18668039.001]
  • [Cites] Am J Med Genet A. 2005 Apr 30;134(3):259-67 [15723295.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2085-8 [9851930.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):157-64 [9063735.001]
  • [Cites] J Clin Invest. 1991 May;87(5):1862-6 [2022752.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):955-7 [15300250.001]
  • [Cites] Hum Mol Genet. 2004 Sep 15;13(18):2043-59 [15254012.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17792-800 [14742428.001]
  • [Cites] Mol Cytogenet. 2008;1:8 [18471269.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):477-88 [18252227.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):667-75 [18184952.001]
  • [Cites] Hum Mol Genet. 2008 Feb 15;17(4):628-38 [18156158.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2007 Nov 15;145C(4):335-45 [17910076.001]
  • [Cites] Genet Med. 2007 Sep;9(9):607-16 [17873649.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1071-3 [17704777.001]
  • [Cites] Hum Mol Genet. 2007 Mar 1;16(5):567-72 [17360722.001]
  • [Cites] Curr Opin Neurol. 2007 Apr;20(2):125-34 [17351481.001]
  • [Cites] Am J Hum Genet. 2007 Feb;80(2):232-40 [17236129.001]
  • [Cites] Am J Med Genet A. 2006 Dec 15;140(24):2757-67 [17103431.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):999-1001 [16906164.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1032-7 [16906163.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1038-42 [16906162.001]
  • [Cites] Methods Mol Biol. 2010;632:125-39 [20217575.001]
  • (PMID = 20587050.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2909945
  •  go-up   go-down


88. Feederle R, Bartlett EJ, Delecluse HJ: Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae; 2010;1(1):6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus genetics: talking about the BAC generation.
  • More recently, HV genomes cloned onto a bacterial artificial chromosome (BAC) have become available.
  • HV BACs can be easily modified in E.coli and reintroduced in eukaryotic cells to produce infectious viruses.
  • Mutants derived from HV BACs have been used both to understand the functions of all types of genetic elements present on the virus genome, but also to generate mutants with potentially medically relevant properties such as preventative vaccines.
  • Here we retrace the development of the BAC technology applied to the Epstein-Barr virus (EBV) and review the strategies available for the construction of mutants.
  • We expand on the appropriate controls required for proper use of the EBV BACs, and on the technical hurdles researchers face in working with these recombinants.
  • Finally, we catalog the EBV BAC mutants that are currently available and illustrate their contributions to the field using a few representative examples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2009 Jun 20;389(1-2):75-81 [19427010.001]
  • [Cites] PLoS Pathog. 2009 Jun;5(6):e1000490 [19557156.001]
  • [Cites] PLoS Pathog. 2009 Jul;5(7):e1000506 [19578441.001]
  • [Cites] PLoS Pathog. 2009 Aug;5(8):e1000547 [19680535.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):e36 [15731329.001]
  • [Cites] J Virol. 2005 Apr;79(7):4506-9 [15767450.001]
  • [Cites] Nucleic Acids Res. 2005;33(16):e137 [16147984.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):360-4 [10207884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5188-93 [10220441.001]
  • [Cites] J Virol. 1999 Aug;73(8):6405-14 [10400733.001]
  • [Cites] J Virol. 1999 Oct;73(10):8320-9 [10482582.001]
  • [Cites] Gene Ther. 1999 May;6(5):922-30 [10505118.001]
  • [Cites] J Virol. 2000 Aug;74(15):6964-74 [10888635.001]
  • [Cites] J Virol. 2000 Nov;74(21):10142-52 [11024143.001]
  • [Cites] J Virol. 2007 Mar;81(6):2957-69 [17215283.001]
  • [Cites] J Virol. 2007 Apr;81(7):3303-16 [17215287.001]
  • [Cites] J Virol. 2010 Mar;84(6):2871-80 [20071577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):850-5 [20080764.001]
  • [Cites] J Virol. 2010 May;84(9):4524-33 [20147387.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 [2556717.001]
  • [Cites] J Virol. 1988 Jul;62(7):2274-84 [2836611.001]
  • [Cites] J Virol. 1981 Apr;38(1):305-16 [6264105.001]
  • [Cites] J Virol. 1981 May;38(2):632-48 [6264134.001]
  • [Cites] J Virol. 1982 Dec;44(3):834-44 [6294333.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):27-32 [6319296.001]
  • [Cites] J Virol. 1995 Aug;69(8):4924-32 [7609061.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14759-63 [9405686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50 [9653172.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):123-8 [9771703.001]
  • [Cites] Hum Gene Ther. 1998 Dec 10;9(18):2787-94 [9874276.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2001 Mar;75(6):2921-8 [11222717.001]
  • [Cites] FEMS Microbiol Lett. 2001 Jul 10;201(1):9-14 [11445160.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):407-14 [11669602.001]
  • [Cites] J Virol. 2003 Jan;77(2):1382-91 [12502854.001]
  • [Cites] J Virol. 2003 May;77(9):5073-83 [12692210.001]
  • [Cites] J Virol. 1992 May;66(5):2893-903 [1313908.001]
  • [Cites] J Gen Virol. 2003 Dec;84(Pt 12):3393-403 [14645920.001]
  • [Cites] J Virol. 2004 Jul;78(13):7004-15 [15194777.001]
  • [Cites] Vaccine. 2004 Sep 28;22(29-30):4069-74 [15364458.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] J Virol. 2005 Mar;79(6):3703-12 [15731264.001]
  • [Cites] Int J Cancer. 2007 Sep 15;121(6):1274-81 [17520680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10989-94 [12947043.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1099-104 [15361873.001]
  • [Cites] J Virol. 2004 Nov;78(21):12082-4 [15479851.001]
  • [Cites] J Virol. 2005 Nov;79(21):13822-8 [16227304.001]
  • [Cites] Biotechniques. 2006 Feb;40(2):191-7 [16526409.001]
  • [Cites] J Virol. 2006 Sep;80(18):9115-33 [16940523.001]
  • [Cites] Expert Rev Vaccines. 2007 Jun;6(3):381-90 [17542753.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jul;7(7):997-1007 [17665989.001]
  • [Cites] Mol Biotechnol. 2009 May;42(1):110-6 [19160076.001]
  • [Cites] J Virol. 2009 May;83(9):4616-23 [19244320.001]
  • [Cites] J Biol Chem. 2009 Aug 7;284(32):21557-68 [19491105.001]
  • [Cites] J Virol. 2009 Nov;83(21):10877-91 [19710145.001]
  • [Cites] J Virol. 2010 Jan;84(2):1139-47 [19889766.001]
  • [Cites] PLoS Pathog. 2010;6(6):e1000951 [20548956.001]
  • [Cites] Nature. 1989 Aug 3;340(6232):393-7 [2547164.001]
  • [Cites] Science. 1989 Jun 16;244(4910):1307-12 [2660262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085-9 [2987963.001]
  • [Cites] Virology. 1984 Feb;133(1):146-57 [6322426.001]
  • [Cites] J Virol. 1996 Oct;70(10):7260-3 [8794379.001]
  • [Cites] J Virol. 2001 Nov;75(21):10334-47 [11581402.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]
  • [Cites] Methods Mol Biol. 2005;292:353-70 [15507720.001]
  • [Cites] J Virol. 2004 Dec;78(23):13376-80 [15542691.001]
  • [Cites] J Virol. 2005 Jan;79(2):841-52 [15613312.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):349-60 [15684323.001]
  • [Cites] J Virol. 2005 Jun;79(12):7338-48 [15919888.001]
  • [Cites] J Virol. 2005 Jun;79(12):7641-7 [15919916.001]
  • [Cites] J Virol. 2005 Aug;79(16):10709-17 [16051863.001]
  • [Cites] J Virol. 2005 Nov;79(22):13984-92 [16254334.001]
  • [Cites] PLoS Biol. 2005 Dec;3(12):e404 [16277553.001]
  • [Cites] J Virol. 2006 May;80(10):5078-81 [16641300.001]
  • [Cites] J Virol. 2006 Jun;80(12):5723-32 [16731911.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Virol. 2006 Oct;80(19):9435-43 [16973549.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19500-5 [17159137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3366-71 [17360652.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] J Virol. 2007 Dec;81(23):13200-8 [17913822.001]
  • [Cites] PLoS Pathog. 2007 Dec;3(12):e194 [18085824.001]
  • [Cites] J Virol. 2008 Mar;82(5):2385-93 [18094150.001]
  • [Cites] J Virol. 2008 Apr;82(8):3903-11 [18272580.001]
  • [Cites] J Virol. 2008 Apr;82(8):4042-51 [18287246.001]
  • [Cites] J Virol. 2008 Jul;82(13):6721-33 [18448526.001]
  • [Cites] Virology. 2008 Dec 20;382(2):145-62 [18937960.001]
  • [Cites] PLoS Pathog. 2009 Jan;5(1):e1000255 [19119421.001]
  • [Cites] J Virol. 2009 May;83(10):4952-62 [19264771.001]
  • (PMID = 21429237.001).
  • [ISSN] 2042-4280
  • [Journal-full-title] Herpesviridae
  • [ISO-abbreviation] Herpesviridae
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3063228
  •  go-up   go-down


89. Xu Q, Anderson SA: Mapping lineage using BAC-Cre reporter lines. Curr Protoc Neurosci; 2010 Jan;Chapter 1:Unit 1.19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mapping lineage using BAC-Cre reporter lines.
  • An effective and versatile approach for tracing lineage of progenitors into adult cell types is to target the promoter of an interested gene with Cre (a phage DNA recombinase) to achieve simultaneous activation during neurogenesis.
  • The bacterial artificial chromosome (BAC) is an efficient Cre carrier.
  • Not only the targeted gene remains diploidy in BAC-Cre transgenic mice, but also the large portions of the gene's regulatory elements to be incorporated in the BAC allow Cre to sufficiently and reliably reproduce the endogenous gene expression pattern.
  • When the BAC-Cre mouse is crossed to a Cre reporter mouse, even Cre is transiently expressed.
  • Experimental designs and procedures for RecA-based BAC DNA modification and preparation for pronuclear injection are highlighted.
  • Suggestions for the use of BAC-Cre transgenic mice in fate-mapping analyses are also provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20066654.001).
  • [ISSN] 1934-8576
  • [Journal-full-title] Current protocols in neuroscience
  • [ISO-abbreviation] Curr Protoc Neurosci
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH066912
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 2.7.7.- / Rec A Recombinases
  •  go-up   go-down


90. Niemi RM, Heiskanen I, Heine R, Rapala J: Previously uncultured beta-Proteobacteria dominate in biologically active granular activated carbon (BAC) filters. Water Res; 2009 Dec;43(20):5075-86
StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Previously uncultured beta-Proteobacteria dominate in biologically active granular activated carbon (BAC) filters.
  • Bacteria colonizing BAC filters used in drinking water purification from lake water were characterized by morphology, physiological tests, whole cell protein profiles and PLFA (phospholipid fatty acid) composition, and identified by partial 16S rRNA gene sequencing.
  • Epifluorescence revealed prothecate bacteria to dominate in BAC.
  • The majority of cultured bacteria persisting in the BAC biofilter were Burkholderiales, which according to ecological information are efficient in the mineralisation of dissolved organic matter in BAC.

  • Hazardous Substances Data Bank. ACTIVATED CHARCOAL .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783028.001).
  • [ISSN] 1879-2448
  • [Journal-full-title] Water research
  • [ISO-abbreviation] Water Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Ribosomal, 16S; 16291-96-6 / Charcoal
  •  go-up   go-down


91. Tian JY, Chen ZL, Yang YL, Liang H, Nan J, Wang ZZ, Li GB: Hybrid process of BAC and sMBR for treating polluted raw water. Bioresour Technol; 2009 Dec;100(24):6243-9
Hazardous Substances Data Bank. ACTIVATED CHARCOAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid process of BAC and sMBR for treating polluted raw water.
  • The hybrid process of biological activated carbon (BAC) and submerged membrane bioreactor (sMBR) was evaluated for the drinking water treatment from polluted raw water, with the respective hydraulic retention time of 0.5 h.
  • The results confirmed the synergetic effects between the BAC and the subsequent sMBR.
  • A moderate amount of ammonium (54.5%) was decreased in the BAC; while the total removal efficiency was increased to 89.8% after the further treatment by the sMBR.
  • In the hybrid process, adsorption of granular activated carbon (in BAC), two stages of biodegradation (in BAC and sMBR), and separation by the membrane (in sMBR) jointly contributed to the removal of organic matter.
  • Due to the pre-treatment effect of BAC, the membrane fouling in the downstream sMBR was substantially mitigated.

  • MedlinePlus Health Information. consumer health - Water Pollution.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682892.001).
  • [ISSN] 1873-2976
  • [Journal-full-title] Bioresource technology
  • [ISO-abbreviation] Bioresour. Technol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membranes, Artificial; 0 / Nitrates; 0 / Organic Chemicals; 0 / Quaternary Ammonium Compounds; 0 / Water Pollutants, Chemical; 16291-96-6 / Charcoal
  •  go-up   go-down


92. Zhao Y, Petherbridge L, Smith LP, Baigent S, Nair V: Self-excision of the BAC sequences from the recombinant Marek's disease virus genome increases replication and pathogenicity. Virol J; 2008 Jan 30;5:19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-excision of the BAC sequences from the recombinant Marek's disease virus genome increases replication and pathogenicity.
  • Cloning of full length genomes of herpesviruses as bacterial artificial chromosomes (BAC) has greatly facilitated the manipulation of the genomes of several herpesviruses to identify the pathogenic determinants.
  • We have previously reported the construction of the BAC clone (pRB-1B5) of the highly oncogenic Marek's disease virus (MDV) strain RB-1B, which has proven to be a valuable resource for elucidating several oncogenic determinants.
  • Despite the retention of the BAC replicon within the genome, the reconstituted virus was able to induce tumours in susceptible chickens.
  • Nevertheless, it was unclear whether the presence of the BAC influenced the full oncogenic potential of the reconstituted virus.
  • To maximize the closeness of BAC-derived virus to the parental RB-1B strain, we modified the existing pRB-1B5 clone by restoring the Us2 and by introducing SV40-cre cassette within the loxP sites of the mini-F plasmid, to allow self-excision of the plasmid sequences in chicken cells.
  • Excision of the BAC sequences also enhanced the pathogenicity to levels similar to that of the parental virus, as the cumulative incidence of Marek's disease in groups infected with the recombinant and the parental viruses showed no significant differences.
  • Thus, we have been able to make significant improvements to the existing BAC clone of this highly oncogenic virus which would certainly increase its usefulness as a valuable tool for studies on identifying the oncogenic determinants of this major avian pathogen.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / genetics. Herpesvirus 2, Gallid / physiology. Marek Disease / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4873-8 [10781094.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1307-17 [16651385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1687-92 [16446447.001]
  • [Cites] J Virol. 2003 May;77(9):5073-83 [12692210.001]
  • [Cites] J Virol. 2000 Dec;74(23):11088-98 [11070004.001]
  • [Cites] Biotechniques. 2006 Feb;40(2):191-7 [16526409.001]
  • [Cites] J Virol. 2002 Mar;76(5):2316-28 [11836410.001]
  • [Cites] J Virol. 2005 Sep;79(18):11647-59 [16140742.001]
  • [Cites] Crit Rev Microbiol. 1986;12(4):293-320 [3007026.001]
  • [Cites] J Virol. 2007 Oct;81(19):10575-87 [17634222.001]
  • [Cites] J Virol. 2004 Dec;78(23):13376-80 [15542691.001]
  • [Cites] Avian Pathol. 2003 Aug;32(4):323-33 [17585455.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Avian Pathol. 1982;11(4):593-605 [18770225.001]
  • [Cites] J Virol Methods. 2005 Jan;123(1):53-64 [15582699.001]
  • [Cites] J Virol. 2005 Jun;79(11):6984-96 [15890938.001]
  • [Cites] Curr Top Microbiol Immunol. 2001;255:25-55 [11217426.001]
  • [Cites] Nat Rev Microbiol. 2006 Apr;4(4):283-94 [16541136.001]
  • (PMID = 18230192.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C506448/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2248170
  •  go-up   go-down


93. Chandler KJ, Chandler RL, Broeckelmann EM, Hou Y, Southard-Smith EM, Mortlock DP: Relevance of BAC transgene copy number in mice: transgene copy number variation across multiple transgenic lines and correlations with transgene integrity and expression. Mamm Genome; 2007 Oct;18(10):693-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of BAC transgene copy number in mice: transgene copy number variation across multiple transgenic lines and correlations with transgene integrity and expression.
  • Bacterial artificial chromosomes (BACs) are excellent tools for manipulating large DNA fragments and, as a result, are increasingly utilized to engineer transgenic mice by pronuclear injection.
  • The demand for BAC transgenic mice underscores the need for careful inspection of BAC integrity and fidelity following transgenesis, which may be crucial for interpreting transgene function.
  • However, there are limited data regarding whether BAC transgenes routinely integrate in the mouse genome as intact molecules, how BAC transgenes behave as they are passed through the germline across successive generations, and how variation in BAC transgene copy number relates to transgene expression.
  • To address these questions, we used TaqMan real-time PCR to estimate BAC transgene copy number in BAC transgenic embryos and lines.
  • In addition, polymorphic marker analysis suggests that the majority of BAC transgenic lines contain intact molecules.
  • Notably, all lines containing multiple BAC copies also contain all BAC-specific markers.
  • Three of 23 founders analyzed contained BAC transgenes integrated into more than one genomic location.
  • Finally, we show increased BAC transgene copy number correlates with increased BAC transgene expression.
  • In sum, our efforts have provided a reliable method for assaying BAC transgene integrity and fidelity, and data that should be useful for researchers using BACs as transgenic vectors.
  • [MeSH-major] Chromosomes, Artificial, Bacterial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 15;164(2):812-24 [10623827.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2934-51 [17283059.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Nat Rev Genet. 2001 Oct;2(10):769-79 [11584293.001]
  • [Cites] Nat Rev Neurosci. 2001 Dec;2(12):861-70 [11733793.001]
  • [Cites] Transgenic Res. 2002 Feb;11(1):43-8 [11874102.001]
  • [Cites] J Biochem Biophys Methods. 2002 Jul 31;52(2):145-9 [12204418.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2069-81 [12915490.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):917-25 [14586460.001]
  • [Cites] Transgenic Res. 2003 Dec;12(6):751-5 [14713206.001]
  • [Cites] Science. 1988 Jun 10;240(4858):1468-74 [3287623.001]
  • [Cites] Mol Biol Med. 1989 Aug;6(4):283-98 [2695741.001]
  • [Cites] Development. 1991 Feb;111(2):531-42 [1893873.001]
  • [Cites] Gene. 1993 Jun 30;128(2):197-202 [8390388.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):126-38 [7589793.001]
  • [Cites] Reprod Nutr Dev. 1996;36(6):607-18 [9021872.001]
  • [Cites] Development. 1997 Jun;124(11):2203-12 [9187146.001]
  • [Cites] Genetics. 1998 Jan;148(1):401-8 [9475750.001]
  • [Cites] Biotechniques. 2004 Oct;37(4):610-3 [15517974.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Nov 4;130(1-2):7-15 [15519671.001]
  • [Cites] Development. 2005 Mar;132(6):1453-61 [15716346.001]
  • [Cites] Dev Dyn. 2006 May;235(5):1413-32 [16586440.001]
  • [Cites] Mamm Genome. 2006 Aug;17(8):791-807 [16897340.001]
  • [Cites] Transgenic Res. 2001 Apr;10(2):83-103 [11305364.001]
  • (PMID = 17882484.001).
  • [ISSN] 0938-8990
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / T32 HD007502; United States / NICHD NIH HHS / HD / T32 HD007502-08; United States / NIGMS NIH HHS / GM / T32 GM062758; United States / NIAMS NIH HHS / AR / R01 AR049529; United States / NIGMS NIH HHS / GM / 1T32GM62758-03; United States / NICHD NIH HHS / HD / R01 HD047880-01; United States / NICHD NIH HHS / HD / 5T32HD07502-08; United States / NIDDK NIH HHS / DK / R21 DK064251; United States / NIDDK NIH HHS / DK / R21 DK064251-01S1; United States / NIGMS NIH HHS / GM / T32 GM062758-03; United States / NICHD NIH HHS / HD / 1R01HD47880-01; United States / NIDDK NIH HHS / DK / R21 DK064251-01; United States / NICHD NIH HHS / HD / R01 HD047880; United States / NIAMS NIH HHS / AR / R01 AR049529-04; United States / NIDDK NIH HHS / DK / R21 DK064251-02; United States / NIAMS NIH HHS / AR / 5R01AR049529-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; 9012-36-6 / Sepharose
  • [Other-IDs] NLM/ NIHMS293875; NLM/ PMC3110064
  •  go-up   go-down


94. Lu XH: BAC to degeneration bacterial artificial chromosome (BAC)-mediated transgenesis for modeling basal ganglia neurodegenerative disorders. Int Rev Neurobiol; 2009;89:37-56
MedlinePlus Health Information. consumer health - Degenerative Nerve Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC to degeneration bacterial artificial chromosome (BAC)-mediated transgenesis for modeling basal ganglia neurodegenerative disorders.
  • Basal ganglia neurodegenerative disorders, such as Parkinson's disease (PD) and Huntington's disease (HD), are characterized by not only spectrum of motor deficits, ranging form hypokinesia to hyperkinesia, but also emotional, cognitive, and psychiatric manifestations.
  • Transgenic approaches using large genomic inserts, such as bacterial artificial chromosome (BAC)-mediated transgenesis, due to its capacity to propagate large-size genomic DNA and faithful production of endogenous-like gene expression pattern/lever, have provided an ideal basis for the generation of transgenic mice as model for basal ganglia neurodegenerative disorders, as well as the functional and structural analysis of neurocircuits.
  • In this chapter, the basic concepts and practical approaches about application of BAC transgenic system are introduced.
  • Existent major BAC transgenic mouse models for PD and HD are evaluated according to their construct, face, and predicative validity.
  • Finally, considerations, possible solutions, and future perspectives of using BAC transgenic approach to study basal ganglia neurodegenerative disorders are discussed.
  • [MeSH-major] Basal Ganglia Diseases / genetics. Chromosomes, Artificial, Bacterial / genetics. Neurodegenerative Diseases / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Huntington Disease / genetics. Huntington Disease / pathology. Mice. Mice, Transgenic. Parkinson Disease / genetics. Parkinson Disease / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900614.001).
  • [ISSN] 0074-7742
  • [Journal-full-title] International review of neurobiology
  • [ISO-abbreviation] Int. Rev. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 117
  •  go-up   go-down


95. Li L, Zhu W, Zhang P, Zhang Q, Zhang Z: TiO2/UV/O3-BAC processes for removing refractory and hazardous pollutants in raw water. J Hazard Mater; 2006 Feb 6;128(2-3):145-9
Hazardous Substances Data Bank. PHTHALIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TiO2/UV/O3-BAC processes for removing refractory and hazardous pollutants in raw water.
  • TiO2/UV/O3-BAC (biological activated carbon) process was employed to treat raw water and compared to UV/O3-BAC process in its optimum parameters (3 mg/L ozone dosage with 15 min oxidation time and 15 min empty bed contact time in BAC).
  • For the dissolved organic carbon (DOC) removal, TiO2/UV/O3-BAC was more efficient than UV/O3-BAC and its synergetic effect is more than that in UV/O(3)-BAC process.
  • GC/MS analysis showed that TiO2/UV/O3-BAC process was effective in removing phthalate esters (PAEs) and persistent organic pollutants (POPs).
  • TiO2/UV/O3-BAC process was also very effective in removing POPs.

  • MedlinePlus Health Information. consumer health - Water Pollution.
  • Hazardous Substances Data Bank. OZONE .
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. ACTIVATED CHARCOAL .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257116.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organic Chemicals; 0 / Phthalic Acids; 0 / Water Pollutants; 15FIX9V2JP / titanium dioxide; 16291-96-6 / Charcoal; 66H7ZZK23N / Ozone; 6O7F7IX66E / phthalic acid; D1JT611TNE / Titanium
  •  go-up   go-down


96. Sparwasser T, Eberl G: BAC to immunology--bacterial artificial chromosome-mediated transgenesis for targeting of immune cells. Immunology; 2007 Jul;121(3):308-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAC to immunology--bacterial artificial chromosome-mediated transgenesis for targeting of immune cells.
  • A powerful development is the bacterial artificial chromosome (BAC) transgenic approach, combining advantages of both conventional transgenic and knock-in gene-targeting strategies.
  • In immunology the potential of BAC transgenic technology has yet to be fully harvested and, combined with a variety of elegant genetic tools, it will allow the analysis of complex immunological processes in vivo.
  • In this short review, we discuss the applications of BACs in immunology, such as identification of regulatory regions, expression and cell-fate mapping, cell ablation, conditional mutations and the generation of humanized mice.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / immunology. Gene Transfer Techniques
  • [MeSH-minor] Animals. Disease Models, Animal. Gene Targeting. Mice. Mice, Transgenic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1990 Sep;9(9):2843-8 [2390972.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):57-63 [17200412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7 [1528894.001]
  • [Cites] Biotechnology. 1992;24:172-8 [1422011.001]
  • [Cites] Nat Genet. 1994 Jan;6(1):84-9 [8136839.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):979-90 [11581319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11334-9 [12165571.001]
  • [Cites] Immunity. 2002 Aug;17(2):211-20 [12196292.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):652-9 [12730667.001]
  • [Cites] Immunity. 2003 Jul;19(1):145-53 [12871646.001]
  • [Cites] Gene. 2003 Oct 2;315:63-9 [14557065.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):64-73 [14691482.001]
  • [Cites] Genesis. 2004 Jan;38(1):39-50 [14755803.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2731-8 [14978070.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Science. 2004 Apr 2;304(5667):104-7 [15064419.001]
  • [Cites] Nat Neurosci. 2004 May;7(5):483 [15114362.001]
  • [Cites] Science. 2004 Jul 9;305(5681):248-51 [15247480.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):921-4 [15340423.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):925-7 [15340424.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5531-9 [15494502.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Apr;73(4):1260-4 [1063407.001]
  • [Cites] J Exp Med. 1986 Jan 1;163(1):1-17 [3510267.001]
  • [Cites] Cell. 1987 Nov 6;51(3):503-12 [2822260.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):576-8 [3683574.001]
  • [Cites] Science. 1988 Jul 1;241(4861):58-62 [2898810.001]
  • [Cites] Science. 1989 Jun 16;244(4910):1307-12 [2660262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):103-7 [2404272.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):859-65 [9306400.001]
  • [Cites] Science. 1998 Apr 10;280(5361):275-8 [9535655.001]
  • [Cites] Stem Cells. 1998;16(3):166-77 [9617892.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1555-7 [10037821.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):593-7 [10376601.001]
  • [Cites] Biotechniques. 1999 Jul;27(1):154-62 [10407678.001]
  • [Cites] Gene Ther. 1999 Mar;6(3):442-7 [10435094.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1080-4 [10446057.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):353-60 [15785761.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1459-66 [15851486.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3067-74 [16116195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16415-20 [16260741.001]
  • [Cites] Immunity. 2005 Dec;23(6):611-20 [16356859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15951-6 [17038503.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6943-7 [1495984.001]
  • (PMID = 17437533.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 43
  • [Other-IDs] NLM/ PMC2265958
  •  go-up   go-down


97. Kubo T, Yamamoto H, Ichimura K, Jida M, Hayashi T, Otani H, Tsukuda K, Sano Y, Kiura K, Toyooka S: DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer; 2009 Sep;65(3):328-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components.
  • We examined the methylation status in 100 specimens of lung adenocarcinomas measuring 2cm or less and with bronchioloalveolar carcinoma (BAC) components (Noguchi types A-C) and then compared the methylation status between noninvasive tumors (Noguchi type A or B) and invasive tumors (Noguchi type C).
  • Our results indicate the involvement of epigenetic alterations in the progression of adenocarcinoma with BAC components.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. DNA Methylation. Genes, p16. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Cadherins / genetics. Cadherins / metabolism. Cyclin D2 / genetics. Cyclin D2 / metabolism. DNA Mutational Analysis. DNA, Neoplasm / metabolism. Disease Progression. Exons. Female. Genes, erbB-1 / genetics. Humans. In Vitro Techniques. Male. Middle Aged. Mutation / genetics. Neoplasm Invasiveness. Receptors, Retinoic Acid / genetics. Receptors, Retinoic Acid / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144441.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cadherins; 0 / Cyclin D2; 0 / DNA, Neoplasm; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  •  go-up   go-down


98. Chianetta JM, Lefebvre M, LeBlanc R, Grignon S: Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder. Schizophr Res; 2008 Oct;105(1-3):86-94
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder.
  • The objectives of the present study were to compare the psychometric properties of two such batteries, the BACS (Brief Assessment of Cognition in Schizophrenia) and the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status).
  • METHODS: The French version of the BACS and the RBANS was administered to 36 patients with schizophrenia and schizoaffective disorder, and 14 healthy controls.
  • Internal consistency was satisfying (global scale reliability alphas of 0.90 for the BACS, and 0.87 for the RBANS), although some sub-scores from the RBANS decreased the overall consistency of the instrument.
  • BACS and RBANS composite scores were highly correlated to verbal, non-verbal and total WAIS-III scores (BACS: r=0.727, 0.865 and 0.857, respectively; RBANS: r=0.843, 0.747 and 0.875, respectively).
  • Patients underperformed controls by a magnitude of 1.81 SD (BACS), and 0.78 SD (RBANS), after adjusting for education.
  • CONCLUSION: The psychometric properties and ease of use of the BACS and the RBANS were overall satisfying.
  • The BACS demonstrated better internal consistency and test-retest reliability than the RBANS and was nominally more sensitive to diagnosis.
  • [MeSH-major] Cognition Disorders / diagnosis. Neuropsychological Tests / statistics & numerical data. Psychotic Disorders / diagnosis. Schizophrenia / diagnosis. Schizophrenic Psychology
  • [MeSH-minor] Adult. Diagnostic and Statistical Manual of Mental Disorders. Female. Humans. Male. Memory Disorders / diagnosis. Memory Disorders / psychology. Practice (Psychology). Psychiatric Status Rating Scales. Psychometrics. Reproducibility of Results. Sensitivity and Specificity. Wechsler Scales

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790606.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


99. Nowak NJ, Snijders AM, Conroy JM, Albertson DG: The BAC resource: tools for array CGH and FISH. Curr Protoc Hum Genet; 2005 Aug;Chapter 4:Unit 4.13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The BAC resource: tools for array CGH and FISH.
  • Bacterial Artificial Chromosome (BAC) vector clones carrying human DNA were chosen as the intermediate templates for the sequencing of the human genome due to their inherent stability and fidelity to the genome sequence from which they were derived.
  • In this unit, we describe a set of protocols for BAC-based array comparative genomic hybridization (aCGH) that comprise the generation of targets for printing solutions onto glass slides, the subsequent hybridization steps, and CGH analysis of a test sample compared to a reference normal sample.
  • The BAC clones through their sequence allow the extent and gene content of numerical aberrations to be delineated by aCGH, and also provide cytogeneticists with tools for subsequent validation or fine mapping studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18428377.001).
  • [ISSN] 1934-8258
  • [Journal-full-title] Current protocols in human genetics
  • [ISO-abbreviation] Curr Protoc Hum Genet
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Feng J, Vick BA, Lee MK, Zhang HB, Jan CC: Construction of BAC and BIBAC libraries from sunflower and identification of linkage group-specific clones by overgo hybridization. Theor Appl Genet; 2006 Jun;113(1):23-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction of BAC and BIBAC libraries from sunflower and identification of linkage group-specific clones by overgo hybridization.
  • Complementary BAC and BIBAC libraries were constructed from nuclear DNA of sunflower cultivar HA 89.
  • The BAC library, constructed with BamHI in the pECBAC1 vector, contains 107,136 clones and has an average insert size of 140 kb.
  • The frequencies of BAC and BIBAC clones carrying chloroplast or mitochondrial DNA sequences were estimated to be 2.35 and 0.04%, respectively, and insert-empty clones were less than 0.5%.
  • Thirty-six overgos were designed and pooled as probes to screen a subset (5.1x) of the BAC and BIBAC libraries.
  • As a result, 195 BAC and BIBAC clones representing 19 linkage groups were identified, including 76 BAC clones and 119 BIBAC clones, further verifying the genome coverage and utility of the libraries.
  • These BAC and BIBAC libraries and linkage group-specific clones provide resources essential for comprehensive research of the sunflower genome.
  • [MeSH-minor] Chromosome Mapping. Chromosomes, Artificial, Bacterial / genetics. Cloning, Molecular. DNA, Plant / genetics. Gene Library. Nucleic Acid Hybridization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Theor Appl Genet. 2004 Sep;109(5):1041-50 [15164176.001]
  • [Cites] Theor Appl Genet. 1994 Oct;89(4):435-41 [24177892.001]
  • [Cites] Theor Appl Genet. 2003 Apr;106(6):1068-74 [12671755.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6535-40 [10339623.001]
  • [Cites] Genetics. 2001 Aug;158(4):1711-24 [11514457.001]
  • [Cites] Theor Appl Genet. 2003 Feb;106(4):599-606 [12595987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7 [1528894.001]
  • [Cites] Plant Physiol. 2004 Apr;134(4):1317-26 [15020742.001]
  • [Cites] Genome. 1994 Oct;37(5):717-25 [18470115.001]
  • [Cites] Theor Appl Genet. 2005 Aug;111(4):630-9 [16049705.001]
  • [Cites] Genome Res. 2000 May;10(5):714-21 [10810094.001]
  • [Cites] Genome. 2001 Apr;44(2):213-21 [11341731.001]
  • [Cites] Mol Genet Genomics. 2002 Feb;266(6):979-87 [11862492.001]
  • [Cites] Theor Appl Genet. 2003 Sep;107(5):958-64 [12898019.001]
  • [Cites] Theor Appl Genet. 2002 Nov;105(6-7):1058-1066 [12582934.001]
  • [Cites] Science. 1987 May 15;236(4803):806-12 [3033825.001]
  • [Cites] Genome Res. 2003 Dec;13(12):2754-8 [14656976.001]
  • [Cites] Genome. 2003 Jun;46(3):514-20 [12834070.001]
  • [Cites] Genome. 2000 Feb;43(1):199-204 [10701131.001]
  • [Cites] Genetics. 2001 Nov;159(3):1231-42 [11729165.001]
  • [Cites] Cytogenet Genome Res. 2003;102(1-4):277-81 [14970717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8135-40 [9653153.001]
  • [Cites] Theor Appl Genet. 2002 Dec;105(8):1151-1158 [12582893.001]
  • [Cites] Nat Genet. 1994 Jan;6(1):84-9 [8136839.001]
  • [Cites] Theor Appl Genet. 2002 Dec;105(8):1124-1136 [12582890.001]
  • [Cites] Nucleic Acids Res. 1998 Nov 1;26(21):4901-9 [9776751.001]
  • [Cites] Genome. 2003 Oct;46(5):870-8 [14608404.001]
  • [Cites] Genome. 2001 Apr;44(2):154-62 [11341724.001]
  • [Cites] Theor Appl Genet. 1995 Jun;90(7-8):1079-86 [24173066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9975-9 [8790442.001]
  • [Cites] Plant J. 1995 Mar;7(3):525-33 [7757120.001]
  • [Cites] Theor Appl Genet. 2003 Apr;106(6):1102-6 [12671759.001]
  • [Cites] Genomics. 1998 Dec 15;54(3):387-97 [9878241.001]
  • [Cites] Theor Appl Genet. 2003 Jan;106(2):269-76 [12582852.001]
  • [Cites] Theor Appl Genet. 1998 Mar;96(3-4):519-25 [24710892.001]
  • [Cites] Genetics. 2004 May;167(1):449-57 [15166168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4487-91 [7753830.001]
  • [Cites] Plant Cell. 2002 Mar;14(3):537-45 [11910002.001]
  • [Cites] Theor Appl Genet. 2004 Apr;108(6):1002-9 [15067385.001]
  • [Cites] Theor Appl Genet. 1995 Jul;91(2):195-9 [24169763.001]
  • [Cites] Genomics. 1995 Sep 20;29(2):413-25 [8666390.001]
  • (PMID = 16612648.001).
  • [ISSN] 0040-5752
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Plant
  •  go-up   go-down






Advertisement